[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Queen Comfort Products lLC\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":173},{"warningLetters":4,"total":53},[5,31,52,73,94,116,132,154],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},2669,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2022-05-17T13:20:00Z\">05\u002F17\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-05-10T04:00:00Z\">05\u002F10\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcolorful-products-corporation-624415-05102022\">Colorful Products Corporation\u003C\u002Fa>","Division of Pharmaceutical Quality Operations IV","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Brian W. Davidson\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Colorful Products Corporation\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2550 Azurite Circle\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Newbury Park\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>91320-1201\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Pharmaceutical Quality Operations IV\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>May 10, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Davidson:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration inspected your drug manufacturing facility, Colorful Products Corporation, FEI 2083633, at 2550 Azurite Circle, from November 8 to November 17, 2021.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We have not received a response from your firm for corrective actions to the observations identified during the inspection in our Form FDA 483.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR211.22).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm manufactures over-the-counter (OTC) topical drug products such as \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;and hand sanitizers\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>. Your Quality Unit (QU) did not provide adequate oversight for the manufacture of your OTC drug products. For example, your QU failed to ensure the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Testing for the identity and strength of the active ingredients was performed and reviewed prior to release for each batch of drug product (21 CFR 211.165(a)).\u003C\u002Fli>\n\t\u003Cli>Thorough investigations for out-of-specifications (OOS) results, complaints, deviations, and other discrepant results per an adequate written and approved procedure (21 CFR 211.192).\u003C\u002Fli>\n\t\u003Cli>Appropriate documentation and assessment of production and process control changes (21 CFR 211.100(a)).\u003C\u002Fli>\n\t\u003Cli>Establishment of an adequate, ongoing stability program (21 CFR 211.166(a)).\u003C\u002Fli>\n\t\u003Cli>Performance of appropriate annual product reviews (21 CFR 211.180(e)).\u003C\u002Fli>\n\t\u003Cli>An adequate QU overseeing all manufacturing operations is necessary to consistently ensure drug quality.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Quality Systems\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; o&nbsp; A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>\n&nbsp; o&nbsp; Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003Cbr>\n&nbsp; o&nbsp; A list of chemical and microbial test methods and specifications used to analyze each lot of your drug product before making a lot disposition decision, and the associated written procedures.\u003C\u002Fp>\n\n\u003Cp>&nbsp; An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\u003C\u002Fp>\n\n\u003Cp>&nbsp; A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003C\u002Fp>\n\n\u003Cp>&nbsp; o&nbsp; A complete and final review of each batch and its related information before the QU disposition decision.\u003Cbr>\n&nbsp; o&nbsp; Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, corrective action and preventive action (CAPA) effectiveness, QU oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\n\t\u003Cli>A comprehensive, independent assessment of your change management system. This assessment should include, but not be limited to, your procedure(s) to ensure changes are justified, reviewed, and approved by your QU. Your change management program should also include provisions for determining change effectiveness.\u003C\u002Fli>\n\t\u003Cli>A comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; o&nbsp; Stability-indicating methods.\u003Cbr>\n&nbsp; o&nbsp; Stability studies for each drug product in its marketed container-closure system before distribution is permitted.\u003Cbr>\n&nbsp; o&nbsp; An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid.\u003Cbr>\n&nbsp; o&nbsp; Detailed definition of the specific attributes to be tested at each station (timepoint).\u003Cbr>\n&nbsp; o&nbsp; All procedures that describe these and other elements of your remediated stability program.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm lacked appropriate process validation for your drug products. For example, you confirmed to our investigator that process validation was not performed for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> or hand sanitizer drug products. In addition, you also did not provide documentation or written procedures for performing process validation. You also confirmed that equipment qualification has not been performed on your \u003Cstrong>(b)(4)\u003C\u002Fstrong> water \u003Cstrong>(b)(4)\u003C\u002Fstrong> or on the equipment (e.g., mixing tanks, filling lines, and packaging lines) used to manufacture your drug products.\u003C\u002Fp>\n\n\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Process Validation\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>See FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>An assessment of each drug product process to ensure that there is a data-driven and scientifically sound program that identifies and controls all sources of variability, such that your production processes will consistently meet appropriate specifications and manufacturing standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, sufficiency of detectability in your monitoring and testing systems (including analytical methods used by you and contract testing labs), quality of input materials, and reliability of each manufacturing process step and control.\u003C\u002Fli>\n\t\u003Cli>A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification, and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\u003C\u002Fli>\n\t\u003Cli>A timeline for performing process performance qualification for each of your marketed drug products.\u003C\u002Fli>\n\t\u003Cli>Your process performance protocols, and written procedures for qualification of equipment and facilities.\u003C\u002Fli>\n\t\u003Cli>A detailed program for designing, validating, maintaining, controlling, and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\u003C\u002Fli>\n\t\u003Cli>Your CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and\u002For sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements, and you failed to establish written procedures for cleaning and maintenance of equipment (21 CFR 211.67(a) &amp; (b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You have not demonstrated that your cleaning practices are adequate to remove contaminants from the shared equipment used to manufacture your OTC drug products and non-drug products. For example, our investigator observed inadequate cleaning and maintenance of your drug manufacturing equipment, specifically:\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Lack of Cleaning Validation\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>You confirmed to our investigator that cleaning validation has not been performed for the equipment (e.g., mixing tanks, hoses, filling lines, and packaging lines) used to manufacture your OTC drug products.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Lack of Equipment Cleaning\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Your firm lacks cleaning and maintenance procedures for your equipment used to manufacture your drug products. While you document the cleaning of your filling lines, you confirmed to our investigator that you do not document the cleaning of other equipment used to manufacture your drug products. In addition, you stated to our investigator that documentation of the filling lines’ cleaning only began in August 2021. Further, our investigator noted missing information for the filling lines' cleaning logs including product description, lot numbers, and cleaning and sanitization start and end times.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Lack of \u003Cstrong>(b)(4)\u003C\u002Fstrong> Sanitization\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Your firm lacks procedures on how to sanitize and maintain your \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm stated that you began sampling your water system in September 2021. Our review of your water system testing results, collected by our investigator, found total plate count (TPC) results of \u003Cstrong>(b)(4)\u003C\u002Fstrong> cfu\u002FmL (\u003Cstrong>(b)(4)\u003C\u002Fstrong> cfu\u002FmL). You stated to our investigator that you resanitized the water system and resampled. Our review of the retest results only found the testing for total organic carbon (TOC). Your firm has not provided evidence that your \u003Cstrong>(b)(4)\u003C\u002Fstrong> is operating in a state of control. In addition, you could not provide a written investigation, including a description of your resanitization activities, a root cause for the elevated microbial results, or an appropriate CAPA.\u003C\u002Fp>\n\n\u003Cp>Inadequate removal of active ingredients and residues from manufacturing equipment during cleaning can result in cross-contamination of your drug products. Furthermore, inadequate cleaning and sanitization of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system can result in microbial contamination of your drug products.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment whether cross-contaminated products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices and encompass each piece of manufacturing equipment used to manufacture more than one product.\u003C\u002Fli>\n\t\u003Cli>A risk assessment for all drugs you have previously produced on equipment shared with industrial products. For each product, assess the risk of potential contamination due to the shared equipment, and provide your plans for addressing the product quality and patient safety risks for any product still in distribution, including potential recalls or market withdrawals.\u003C\u002Fli>\n\t\u003Cli>Your plans regarding the manufacture of both pharmaceutical and nonpharmaceutical products at your facility. If you intend to continue to manufacture both pharmaceutical and non-pharmaceutical products at your facility, provide your plan to separate the areas in which you will maintain dedicated manufacturing equipment for your pharmaceutical manufacturing and industrial product manufacturing operations.\u003C\u002Fli>\n\t\u003Cli>A CAPA plan, based on the retrospective assessment of your cleaning program, that includes appropriate remediations to your cleaning processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning. Describe improvements to your cleaning program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning execution for all products and equipment; and all other needed remediations.\u003C\u002Fli>\n\t\u003Cli>Appropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include but not be limited to identification and evaluation of all worst-case:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; o&nbsp; drugs with higher toxicities\u003Cbr>\n&nbsp; o&nbsp; drugs with higher drug potencies\u003Cbr>\n&nbsp; o&nbsp; drugs of lower solubility in their cleaning solvents\u003Cbr>\n&nbsp; o&nbsp; drugs with characteristics that make them difficult to clean\u003Cbr>\n&nbsp; o&nbsp; swabbing locations for areas that are most difficult to clean\u003Cbr>\n&nbsp; o&nbsp; maximum hold times before cleaning\u003C\u002Fp>\n\n\u003Cp>In addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A summary of updated standard operating procedures (SOPs) that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\u003C\u002Fli>\n\t\u003Cli>A comprehensive independent assessment of your water system design, control, and maintenance, and corresponding CAPAs.\u003C\u002Fli>\n\t\u003Cli>A thorough remediation plan to install and operate a suitable water system. Include a robust ongoing control, maintenance, and monitoring program to ensure the remediated system design or new system consistently produces water adhering to \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water, USP monograph specifications and appropriate microbial limits (total counts, objectionable microbes).\u003C\u002Fli>\n\t\u003Cli>Regarding the latter, ensure that your total microbial count limit for water is appropriate in view of the intended use of the products produced by your firm.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>4. Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records. (21 CFR 211.68(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm lacked controls to assure the integrity of \u003Cstrong>(b)(4)\u003C\u002Fstrong> used in the manufacturing of your drug products. For example, your firm utilized software (i.e., \u003Cstrong>(b)(4)\u003C\u002Fstrong>) for the retention of data, including your drug product formulations and the quarantine and release status of drug products. This software is also used to document the completion of manufacturing steps on batch records, including \u003Cstrong>(b)(4)\u003C\u002Fstrong> amounts, manufacturing activities, and calculations. You stated to our investigator that this \u003Cstrong>(b)(4)\u003C\u002Fstrong> software was not validated and lacked audit trails.\u003C\u002Fp>\n\n\u003Cp>In addition, your firm lacked adequate controls to ensure that actions are attributed to authorized individuals with unique and unshared login credentials. For example, our investigator observed that the login credentials of employee, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, were used to document the completion of several manufacturing activities on two drug product batch records dated March 17, 2021, and July 19, 2021. However, you stated to our investigator that \u003Cstrong>(b)(4)\u003C\u002Fstrong> has not been employed at the company since September 2019. Further, it was observed that login credentials including “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” were used to document the completion of several manufacturing activities. You stated to our investigator that these login credentials were shared by multiple employees. Shared login credentials are unacceptable, as this practice prevents the identification of specific individuals accessing a controlled system.\u003C\u002Fp>\n\n\u003Cp>Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document Data Integrity and Compliance With Drug CGMP for guidance on establishing and following CGMP compliant data integrity practices at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F97005\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F97005\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>We strongly recommend that you retain a qualified consultant to assist in your remediation. In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive investigation into the extent of the inaccuracies in data records and reporting, including results of the data review for drugs distributed to the United States. Include a detailed description of the scope and root causes of your data integrity lapses.\u003C\u002Fli>\n\t\u003Cli>A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\u003C\u002Fli>\n\t\u003Cli>A management strategy for your firm that includes the details of your global corrective action and preventive action plan. The detailed corrective action plan should describe how you intend to ensure the reliability and completeness of all data generated by your firm including microbiological and analytical data, manufacturing records, and all data submitted to FDA.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003Cbr>\n\u003Cbr>\n\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a [drug] manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to ORAPHARM4_Responses@FDA.HHS.GOV or mail your reply to:\u003C\u002Fp>\n\n\u003Cp>CDR Steven E. Porter, Jr.\u003Cbr>\nDirector, Division of Pharmaceutical Quality Operations IV\u003Cbr>\nU.S. Food &amp; Drug Administration\u003Cbr>\n19701 Fairchild Road\u003Cbr>\nIrvine, California 92612-2506\u003C\u002Fp>\n\n\u003Cp>Please identify your responses with the unique identifier: \u003Cstrong>CMS 624415\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding the contents of this letter, please contact Santiago Gallardo Johnson, Acting Compliance Officer via email at, Santiago.GallardoJohnson@fda.hhs.gov or by telephone at 619-941-3760.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>CDR Steven E. Porter, Jr.\u003Cbr>\nDirector, Division of Pharmaceutical Quality Operations IV\u003C\u002Fp>\n\n\u003Cp>__________________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the&nbsp;Guidance for Industry: \u003Cem>Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19)\u003C\u002Fem> on March 19, 2020, and subsequently updated the guidance several times. The guidance was withdrawn effective December 31, 2021 (86 Fed Reg at 56960). This guidance communicated the Agency’s temporary policy that we did not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&amp;C Act if such firms prepared alcohol-based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances included preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. A review of the formulations of the drug products indicates that such products were not prepared consistent with FDA’s temporary policy set forth in the guidance. Because Colorful Products Corporation hand sanitizer drug products were not consistent with the formulations described in these guidances, they did not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer drug products for violations of section 505 of the FD&amp;C Act.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Brian W. Davidson\n\nRecipient Title\n\nCEO\n\nColorful Products Corporation\n\n2550 Azurite Circle\n\nNewbury Park, CA 91320-1201\n\nUnited States\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations IV\n\nUnited States\n\nWARNING LETTER\n\nMay 10, 2022\n\nDear Mr. Davidson:\n\nThe U.S. Food and Drug Administration inspected your drug manufacturing facility, Colorful Products Corporation, FEI 2083633, at 2550 Azurite Circle, from November 8 to November 17, 2021.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe have not received a response from your firm for corrective actions to the observations identified during the inspection in our Form FDA 483.\n\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n\n1. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR211.22).\n\nYour firm manufactures over-the-counter (OTC) topical drug products such as (b)(4) and hand sanitizers1. Your Quality Unit (QU) did not provide adequate oversight for the manufacture of your OTC drug products. For example, your QU failed to ensure the following:\n\nTesting for the identity and strength of the active ingredients was performed and reviewed prior to release for each batch of drug product (21 CFR 211.165(a)).\n\nThorough investigations for out-of-specifications (OOS) results, complaints, deviations, and other discrepant results per an adequate written and approved procedure (21 CFR 211.192).\n\nAppropriate documentation and assessment of production and process control changes (21 CFR 211.100(a)).\n\nEstablishment of an adequate, ongoing stability program (21 CFR 211.166(a)).\n\nPerformance of appropriate annual product reviews (21 CFR 211.180(e)).\n\nAn adequate QU overseeing all manufacturing operations is necessary to consistently ensure drug quality.\n\nQuality Systems\n\nYour firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\nIn response to this letter, provide the following:\n\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate.\n\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\n\no A list of chemical and microbial test methods and specifications used to analyze each lot of your drug product before making a lot disposition decision, and the associated written procedures.\n\n An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\n\n A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\n\no A complete and final review of each batch and its related information before the QU disposition decision.\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\n\nA comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, corrective action and preventive action (CAPA) effectiveness, QU oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\n\nA comprehensive, independent assessment of your change management system. This assessment should include, but not be limited to, your procedure(s) to ensure changes are justified, reviewed, and approved by your QU. Your change management program should also include provisions for determining change effectiveness.\n\nA comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\n\no Stability-indicating methods.\n\no Stability studies for each drug product in its marketed container-closure system before distribution is permitted.\n\no An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid.\n\no Detailed definition of the specific attributes to be tested at each station (timepoint).\n\no All procedures that describe these and other elements of your remediated stability program.\n\n2. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\n\nYour firm lacked appropriate process validation for your drug products. For example, you confirmed to our investigator that process validation was not performed for your (b)(4) or hand sanitizer drug products. In addition, you also did not provide documentation or written procedures for performing process validation. You also confirmed that equipment qualification has not been performed on your (b)(4) water (b)(4) or on the equipment (e.g., mixing tanks, filling lines, and packaging lines) used to manufacture your drug products.\n\nProcess validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\n\nProcess Validation\n\nSee FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\n\nIn response to this letter, provide the following:\n\nAn assessment of each drug product process to ensure that there is a data-driven and scientifically sound program that identifies and controls all sources of variability, such that your production processes will consistently meet appropriate specifications and manufacturing standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, sufficiency of detectability in your monitoring and testing systems (including analytical methods used by you and contract testing labs), quality of input materials, and reliability of each manufacturing process step and control.\n\nA detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification, and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\n\nA timeline for performing process performance qualification for each of your marketed drug products.\n\nYour process performance protocols, and written procedures for qualification of equipment and facilities.\n\nA detailed program for designing, validating, maintaining, controlling, and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\n\nYour CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\n\n3. Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and\u002For sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements, and you failed to establish written procedures for cleaning and maintenance of equipment (21 CFR 211.67(a) & (b)).\n\nYou have not demonstrated that your cleaning practices are adequate to remove contaminants from the shared equipment used to manufacture your OTC drug products and non-drug products. For example, our investigator observed inadequate cleaning and maintenance of your drug manufacturing equipment, specifically:\n\nLack of Cleaning Validation\n\nYou confirmed to our investigator that cleaning validation has not been performed for the equipment (e.g., mixing tanks, hoses, filling lines, and packaging lines) used to manufacture your OTC drug products.\n\nLack of Equipment Cleaning\n\nYour firm lacks cleaning and maintenance procedures for your equipment used to manufacture your drug products. While you document the cleaning of your filling lines, you confirmed to our investigator that you do not document the cleaning of other equipment used to manufacture your drug products. In addition, you stated to our investigator that documentation of the filling lines’ cleaning only began in August 2021. Further, our investigator noted missing information for the filling lines' cleaning logs including product description, lot numbers, and cleaning and sanitization start and end times.\n\nLack of (b)(4) Sanitization\n\nYour firm lacks procedures on how to sanitize and maintain your (b)(4). Your firm stated that you began sampling your water system in September 2021. Our review of your water system testing results, collected by our investigator, found total plate count (TPC) results of (b)(4) cfu\u002FmL ((b)(4) cfu\u002FmL). You stated to our investigator that you resanitized the water system and resampled. Our review of the retest results only found the testing for total organic carbon (TOC). Your firm has not provided evidence that your (b)(4) is operating in a state of control. In addition, you could not provide a written investigation, including a description of your resanitization activities, a root cause for the elevated microbial results, or an appropriate CAPA.\n\nInadequate removal of active ingredients and residues from manufacturing equipment during cleaning can result in cross-contamination of your drug products. Furthermore, inadequate cleaning and sanitization of your (b)(4) water system can result in microbial contamination of your drug products.\n\nIn response to this letter, provide the following:\n\nA comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment whether cross-contaminated products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices and encompass each piece of manufacturing equipment used to manufacture more than one product.\n\nA risk assessment for all drugs you have previously produced on equipment shared with industrial products. For each product, assess the risk of potential contamination due to the shared equipment, and provide your plans for addressing the product quality and patient safety risks for any product still in distribution, including potential recalls or market withdrawals.\n\nYour plans regarding the manufacture of both pharmaceutical and nonpharmaceutical products at your facility. If you intend to continue to manufacture both pharmaceutical and non-pharmaceutical products at your facility, provide your plan to separate the areas in which you will maintain dedicated manufacturing equipment for your pharmaceutical manufacturing and industrial product manufacturing operations.\n\nA CAPA plan, based on the retrospective assessment of your cleaning program, that includes appropriate remediations to your cleaning processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning. Describe improvements to your cleaning program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning execution for all products and equipment; and all other needed remediations.\n\nAppropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include but not be limited to identification and evaluation of all worst-case:\n\no drugs with higher toxicities\n\no drugs with higher drug potencies\n\no drugs of lower solubility in their cleaning solvents\n\no drugs with characteristics that make them difficult to clean\n\no swabbing locations for areas that are most difficult to clean\n\no maximum hold times before cleaning\n\nIn addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\n\nA summary of updated standard operating procedures (SOPs) that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\n\nA comprehensive independent assessment of your water system design, control, and maintenance, and corresponding CAPAs.\n\nA thorough remediation plan to install and operate a suitable water system. Include a robust ongoing control, maintenance, and monitoring program to ensure the remediated system design or new system consistently produces water adhering to (b)(4) Water, USP monograph specifications and appropriate microbial limits (total counts, objectionable microbes).\n\nRegarding the latter, ensure that your total microbial count limit for water is appropriate in view of the intended use of the products produced by your firm.\n\n4. Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records. (21 CFR 211.68(b)).\n\nYour firm lacked controls to assure the integrity of (b)(4) used in the manufacturing of your drug products. For example, your firm utilized software (i.e., (b)(4)) for the retention of data, including your drug product formulations and the quarantine and release status of drug products. This software is also used to document the completion of manufacturing steps on batch records, including (b)(4) amounts, manufacturing activities, and calculations. You stated to our investigator that this (b)(4) software was not validated and lacked audit trails.\n\nIn addition, your firm lacked adequate controls to ensure that actions are attributed to authorized individuals with unique and unshared login credentials. For example, our investigator observed that the login credentials of employee, (b)(4), were used to document the completion of several manufacturing activities on two drug product batch records dated March 17, 2021, and July 19, 2021. However, you stated to our investigator that (b)(4) has not been employed at the company since September 2019. Further, it was observed that login credentials including “(b)(4)” and “(b)(4)” were used to document the completion of several manufacturing activities. You stated to our investigator that these login credentials were shared by multiple employees. Shared login credentials are unacceptable, as this practice prevents the identification of specific individuals accessing a controlled system.\n\nYour quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document Data Integrity and Compliance With Drug CGMP for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F97005\u002Fdownload.\n\nWe strongly recommend that you retain a qualified consultant to assist in your remediation. In response to this letter, provide the following:\n\nA comprehensive investigation into the extent of the inaccuracies in data records and reporting, including results of the data review for drugs distributed to the United States. Include a detailed description of the scope and root causes of your data integrity lapses.\n\nA current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\n\nA management strategy for your firm that includes the details of your global corrective action and preventive action plan. The detailed corrective action plan should describe how you intend to ensure the reliability and completeness of all data generated by your firm including microbiological and analytical data, manufacturing records, and all data submitted to FDA.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a [drug] manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to ORAPHARM4_Responses@FDA.HHS.GOV or mail your reply to:\n\nCDR Steven E. Porter, Jr.\n\nDirector, Division of Pharmaceutical Quality Operations IV\n\nU.S. Food & Drug Administration\n\n19701 Fairchild Road\n\nIrvine, California 92612-2506\n\nPlease identify your responses with the unique identifier: CMS 624415.\n\nIf you have questions regarding the contents of this letter, please contact Santiago Gallardo Johnson, Acting Compliance Officer via email at, Santiago.GallardoJohnson@fda.hhs.gov or by telephone at 619-941-3760.\n\nSincerely,\n\n\u002FS\u002F\n\nCDR Steven E. Porter, Jr.\n\nDirector, Division of Pharmaceutical Quality Operations IV\n\n__________________________________\n\n1 Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) on March 19, 2020, and subsequently updated the guidance several times. The guidance was withdrawn effective December 31, 2021 (86 Fed Reg at 56960). This guidance communicated the Agency’s temporary policy that we did not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&C Act if such firms prepared alcohol-based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances included preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. A review of the formulations of the drug products indicates that such products were not prepared consistent with FDA’s temporary policy set forth in the guidance. Because Colorful Products Corporation hand sanitizer drug products were not consistent with the formulations described in these guidances, they did not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer drug products for violations of section 505 of the FD&C Act.","Colorful Products Corporation","colorful-products-corporation-624415-05102022","2026-08-18T06:42:29.262718+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcolorful-products-corporation-624415-05102022","2026-10-26T08:08:17.023041+00:00","Warning Letter","Issued","2022-05-17","624415","Drugs","Mr. Brian W. Davidson","2026-08-20T01:53:42.803+00:00","VIA UPS","2022-05-10",{"id":32,"raw":33,"subject":38,"body_html":39,"body_text":40,"firm_name":41,"letter_id":42,"created_at":43,"fei_number":19,"letter_url":44,"updated_at":45,"action_type":22,"case_status":23,"posted_date":46,"marcs_cms_no":47,"product_type":48,"closeout_date":19,"issuing_office":37,"recipient_name":49,"body_fetched_at":50,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":51,"medical_device_id":19,"response_letter_date":19},3332,[34,35,36,37,38,13,13,13],"\u003Ctime datetime=\"2021-05-26T15:00:00Z\">05\u002F26\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-05-20T04:00:00Z\">05\u002F20\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fns-products-inc-605706-05202021\">NS Products, Inc.\u003C\u002Fa>","Center for Food Safety and Applied Nutrition","New Drug\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Dietary Supplements                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Wolfe Vaughn and Craig Sheralyn\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>NS Products, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>11721 State Ave\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Marysville\u003C\u002Fspan>, \u003Cspan>WA\u003C\u002Fspan> \u003Cspan>98271\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Food Safety and Applied Nutrition\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n         \n          \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan> Federal Trade Commission\u003C\u002Fdd>\n\n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>May 20, 2021\u003Cbr>\n\u003Cbr>\nRE: 605706\u003C\u002Fp>\n\n\u003Cp>Dear Wolfe Vaughn and Craig Sheralyn:\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the Food and Drug Administration (FDA) reviewed your website at the Internet address, www.naturacure.net in March 2021 and has determined that you take orders there for the product “NaturaCure.” You are also advised that the Federal Trade Commission reviewed your website in May 2021.\u003C\u002Fp>\n\n\u003Cp>The claims on your website establish that the product is a drug under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)(B)] because it is intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that your product is intended for use as a drug include the following:\u003C\u002Fp>\n\n\u003Cp>On the home page:\u003Cbr>\n• “You avoid expensive surgical procedures, injections and ineffective treatments. . . NaturaCure may replace conventional fertility treatments….”\u003C\u002Fp>\n\n\u003Cp>On the “ABOUT FERTILITY” page:\u003Cbr>\n• “NaturaCure works with your body, eliminating the root cause of your specific infertility disorder (such as: ovarian cysts, uterine fibroids, endometriosis, high FSH, PCOS etc.)….”\u003Cbr>\n\u003Cbr>\n• “You will get pregnant very fast and give birth to healthy children regardless of . . . how severe or chronic your infertility disorder.”\u003C\u002Fp>\n\n\u003Cp>On the “HOW IT WORKS” page:\u003Cbr>\n• “If you suffer from infertility, tried every prescription, patch and injection the doctors have prescribed but nothing works – and want a solution that really works – then you need to try . . . NaturaCure.”\u003Cbr>\n• “Depending on individual customers and the types of infertility treated, success rates ranged from about 50% up to 98%. Included in these statistics are cases of infertility involving: . . . Obstruction of the fallopian tubess [sic] [,] Amenorrhea[,] Absent ovulation[,] Endometriosis[,] Uterine fibroids[,] . . . None liquidification of semen [sic][,] Tubal blockage[,] . . . Previous tubal ligation”\u003Cbr>\n• “Discovery NaturaCure’s Award Winning Herbal Formulation”\u003Cbr>\no “Bee Propolis - is beneficial for autoimmune related fertility issues such as recurrent miscarriage due to immunological response (mother's body attacks and rejects the fetus), autoimmune related premature ovarian failure and antisperm antibody.”\u003Cbr>\no “Raspberry Fruit - Relieves impotence . . .”\u003C\u002Fp>\n\n\u003Cp>Your website also contains evidence of intended use in the form of personal testimonials recommending or describing the use of NaturaCure for the cure, mitigation, treatment, or prevention of disease. Examples of such testimonials include:\u003C\u002Fp>\n\n\u003Cp>On the “CUSTOMER REVIEWS” page:\u003Cbr>\n• “I had a miscarriage in June 2010 &amp; have been trying to conceive ever since . . . In April 2011 I decided to order NaturaCure. Started taking it in May &amp; I am now 7 weeks pregnant! . . . THIS REALLY WORKS!!!!”\u003C\u002Fp>\n\n\u003Cp>Your product “NaturaCure” is not generally recognized as safe and effective for the above referenced uses and, therefore, the product is a “new drug” under section 201(p) of the Act [21 U.S.C. § 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. §§ 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 C.F.R. § 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003Cbr>\n\u003Cbr>\nYour product “NaturaCure” is intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purposes. Accordingly, “NaturaCure” fails to bear adequate directions for its intended use and, therefore, the product is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of this misbranded drug violates section 301(a) of the Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your written reply should be directed to Aaron Dotson, Compliance Officer, United States Food and Drug Administration, Center for Food Safety and Applied Nutrition, 5001 Campus Drive, Office of Compliance (HFS-608), Division of Enforcement, College Park, Maryland 20740-3835. If you have any questions, you may also contact Aaron Dotson at aaron.dotson@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>In addition, the Federal Trade Commission has determined that it is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess a reasonable basis consisting of competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made. \u003Cem>POM Wonderful LLC\u003C\u002Fem>, 155 F.T.C. 1, 60-61, (2013),&nbsp;\u003Cem>aff’d in relevant part\u003C\u002Fem>, 777 F.3d 478 (D.C. Cir. 2015); \u003Cem>Daniel Chapter One\u003C\u002Fem>, FTC Dkt. No. 9239, 2009 WL 5160000 at *16-19 (F.T.C. Dec. 24, 2009), \u003Cem>aff’d\u003C\u002Fem>, 405 Fed. Appx. 505 (D.C. Cir. 2010);&nbsp;\u003Cem>Removatron Int'l Corp\u003C\u002Fem>., 111 F.T.C. 206, 297-99 (1988), \u003Cem>aff’d\u003C\u002Fem>, 884 F.2d 1489, 1496 (1stCir. 1989); see also, \u003Cem>FTC v. Direct Mktg. Concepts\u003C\u002Fem>, 569 F. Supp. 2d 285, 300, 303 (D. Mass. 2008), \u003Cem>aff’d\u003C\u002Fem>, 624 F.3d 1 (1st Cir. 2010); \u003Cem>FTC v. Nat'l Urological Group, Inc\u003C\u002Fem>., 645 F. Supp. 2d 1167, 1190, 1202 (N.D. Ga. 2008), \u003Cem>aff’d\u003C\u002Fem>, 356 Fed. Appx. 358 (11th Cir. 2009); \u003Cem>FTC v. Natural Solution, Inc\u003C\u002Fem>., No. CV 06- 6112-JFW, 2007-2 Trade Cas. (CCH) P75,866, 2007 U.S. Dist. LEXIS 60783, at *11-12 (C.D. Cal. Aug. 7, 2007). More generally, to make or exaggerate such claims, whether directly or indirectly, through the use of a product name, website name, metatags, or other means, without rigorous scientific evidence sufficient to substantiate the claims, violates the FTC Act.&nbsp;\u003Cem>See Daniel Chapter One\u003C\u002Fem>, WL 5160000 at *17-19.\u003C\u002Fp>\n\n\u003Cp>The FTC is concerned that one or more of the efficacy claims cited above may not be substantiated by competent and reliable scientific evidence. The FTC strongly urges you to review all claims for your products and ensure that those claims are supported by competent and reliable scientific evidence. Violations of the FTC Act may result in legal action seeking a Federal District Court injunction or Administrative Cease and Desist Order. In addition, marketers who make deceptive claims about the treatment, cure, prevention, or mitigation of a disease may be subject to a civil penalty of up to $43,792 per violation pursuant to Section 5(m)(1)(B) of the FTC Act, 15 U.S.C. § 45(m)(1)(B), and may be required to pay refunds to consumers or provide other relief pursuant to Section 19(b) of the FTC Act, 15 U.S.C. § 57b(b). With regard to the advertising claims discussed above, please notify Richard Cleland of the FTC via electronic mail at rcleland@ftc.govwithin fifteen (15) working days of receipt of this letter, of the specific actions you have taken to address FTC's concerns. If you have any questions regarding compliance with the FTC Act, please contact Mr. Cleland at 202-326-3088.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Michael W. Roosevelt\u003Cbr>\nActing Director\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Food Safety and\u003Cbr>\nApplied Nutrition\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nSerena Viswanathan\u003Cbr>\nAssociate Director\u003Cbr>\nDivision of Advertising Practices\u003Cbr>\nFederal Trade Commission\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDietary Supplements\n\nRecipient:\n\nRecipient Name\n\nWolfe Vaughn and Craig Sheralyn\n\nNS Products, Inc.\n\n11721 State Ave\n\nMarysville, WA 98271\n\nUnited States\n\nIssuing Office:\n\nCenter for Food Safety and Applied Nutrition\n\nUnited States\n\nFederal Trade Commission\n\nWARNING LETTER\n\nMay 20, 2021\n\nRE: 605706\n\nDear Wolfe Vaughn and Craig Sheralyn:\n\nThis is to advise you that the Food and Drug Administration (FDA) reviewed your website at the Internet address, www.naturacure.net in March 2021 and has determined that you take orders there for the product “NaturaCure.” You are also advised that the Federal Trade Commission reviewed your website in May 2021.\n\nThe claims on your website establish that the product is a drug under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)(B)] because it is intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nExamples of some of the website claims that provide evidence that your product is intended for use as a drug include the following:\n\nOn the home page:\n\n• “You avoid expensive surgical procedures, injections and ineffective treatments. . . NaturaCure may replace conventional fertility treatments….”\n\nOn the “ABOUT FERTILITY” page:\n\n• “NaturaCure works with your body, eliminating the root cause of your specific infertility disorder (such as: ovarian cysts, uterine fibroids, endometriosis, high FSH, PCOS etc.)….”\n\n• “You will get pregnant very fast and give birth to healthy children regardless of . . . how severe or chronic your infertility disorder.”\n\nOn the “HOW IT WORKS” page:\n\n• “If you suffer from infertility, tried every prescription, patch and injection the doctors have prescribed but nothing works – and want a solution that really works – then you need to try . . . NaturaCure.”\n\n• “Depending on individual customers and the types of infertility treated, success rates ranged from about 50% up to 98%. Included in these statistics are cases of infertility involving: . . . Obstruction of the fallopian tubess [sic] [,] Amenorrhea[,] Absent ovulation[,] Endometriosis[,] Uterine fibroids[,] . . . None liquidification of semen [sic][,] Tubal blockage[,] . . . Previous tubal ligation”\n\n• “Discovery NaturaCure’s Award Winning Herbal Formulation”\n\no “Bee Propolis - is beneficial for autoimmune related fertility issues such as recurrent miscarriage due to immunological response (mother's body attacks and rejects the fetus), autoimmune related premature ovarian failure and antisperm antibody.”\n\no “Raspberry Fruit - Relieves impotence . . .”\n\nYour website also contains evidence of intended use in the form of personal testimonials recommending or describing the use of NaturaCure for the cure, mitigation, treatment, or prevention of disease. Examples of such testimonials include:\n\nOn the “CUSTOMER REVIEWS” page:\n\n• “I had a miscarriage in June 2010 & have been trying to conceive ever since . . . In April 2011 I decided to order NaturaCure. Started taking it in May & I am now 7 weeks pregnant! . . . THIS REALLY WORKS!!!!”\n\nYour product “NaturaCure” is not generally recognized as safe and effective for the above referenced uses and, therefore, the product is a “new drug” under section 201(p) of the Act [21 U.S.C. § 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. §§ 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 C.F.R. § 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour product “NaturaCure” is intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purposes. Accordingly, “NaturaCure” fails to bear adequate directions for its intended use and, therefore, the product is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of this misbranded drug violates section 301(a) of the Act [21 U.S.C. § 331(a)].\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour written reply should be directed to Aaron Dotson, Compliance Officer, United States Food and Drug Administration, Center for Food Safety and Applied Nutrition, 5001 Campus Drive, Office of Compliance (HFS-608), Division of Enforcement, College Park, Maryland 20740-3835. If you have any questions, you may also contact Aaron Dotson at aaron.dotson@fda.hhs.gov.\n\nIn addition, the Federal Trade Commission has determined that it is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess a reasonable basis consisting of competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made. POM Wonderful LLC, 155 F.T.C. 1, 60-61, (2013), aff’d in relevant part, 777 F.3d 478 (D.C. Cir. 2015); Daniel Chapter One, FTC Dkt. No. 9239, 2009 WL 5160000 at *16-19 (F.T.C. Dec. 24, 2009), aff’d, 405 Fed. Appx. 505 (D.C. Cir. 2010); Removatron Int'l Corp., 111 F.T.C. 206, 297-99 (1988), aff’d, 884 F.2d 1489, 1496 (1stCir. 1989); see also, FTC v. Direct Mktg. Concepts, 569 F. Supp. 2d 285, 300, 303 (D. Mass. 2008), aff’d, 624 F.3d 1 (1st Cir. 2010); FTC v. Nat'l Urological Group, Inc., 645 F. Supp. 2d 1167, 1190, 1202 (N.D. Ga. 2008), aff’d, 356 Fed. Appx. 358 (11th Cir. 2009); FTC v. Natural Solution, Inc., No. CV 06- 6112-JFW, 2007-2 Trade Cas. (CCH) P75,866, 2007 U.S. Dist. LEXIS 60783, at *11-12 (C.D. Cal. Aug. 7, 2007). More generally, to make or exaggerate such claims, whether directly or indirectly, through the use of a product name, website name, metatags, or other means, without rigorous scientific evidence sufficient to substantiate the claims, violates the FTC Act. See Daniel Chapter One, WL 5160000 at *17-19.\n\nThe FTC is concerned that one or more of the efficacy claims cited above may not be substantiated by competent and reliable scientific evidence. The FTC strongly urges you to review all claims for your products and ensure that those claims are supported by competent and reliable scientific evidence. Violations of the FTC Act may result in legal action seeking a Federal District Court injunction or Administrative Cease and Desist Order. In addition, marketers who make deceptive claims about the treatment, cure, prevention, or mitigation of a disease may be subject to a civil penalty of up to $43,792 per violation pursuant to Section 5(m)(1)(B) of the FTC Act, 15 U.S.C. § 45(m)(1)(B), and may be required to pay refunds to consumers or provide other relief pursuant to Section 19(b) of the FTC Act, 15 U.S.C. § 57b(b). With regard to the advertising claims discussed above, please notify Richard Cleland of the FTC via electronic mail at rcleland@ftc.govwithin fifteen (15) working days of receipt of this letter, of the specific actions you have taken to address FTC's concerns. If you have any questions regarding compliance with the FTC Act, please contact Mr. Cleland at 202-326-3088.\n\nSincerely,\n\n\u002FS\u002F\n\nMichael W. Roosevelt\n\nActing Director\n\nOffice of Compliance\n\nCenter for Food Safety and\n\nApplied Nutrition\n\nFood and Drug Administration\n\nSincerely,\n\n\u002FS\u002F\n\nSerena Viswanathan\n\nAssociate Director\n\nDivision of Advertising Practices\n\nFederal Trade Commission","NS Products, Inc.","ns-products-inc-605706-05202021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fns-products-inc-605706-05202021","2026-10-26T08:09:35.524317+00:00","2021-05-26","605706","Dietary Supplements","Wolfe Vaughn and Craig Sheralyn","2026-08-20T03:06:45.755+00:00","2021-05-20",{"id":53,"raw":54,"subject":12,"body_html":59,"body_text":60,"firm_name":61,"letter_id":62,"created_at":63,"fei_number":19,"letter_url":64,"updated_at":65,"action_type":22,"case_status":23,"posted_date":66,"marcs_cms_no":67,"product_type":68,"closeout_date":19,"issuing_office":58,"recipient_name":69,"body_fetched_at":70,"delivery_method":71,"recipient_title":19,"reference_number":19,"action_taken_date":72,"medical_device_id":19,"response_letter_date":19},8,[55,56,57,58,12,13,13,13],"\u003Ctime datetime=\"2026-07-28T04:00:00Z\">07\u002F28\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-06-12T04:00:00Z\">06\u002F12\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fahc-products-inc-728604-06122026\">AHC Products, Inc. \u003C\u002Fa>","Center for Veterinary Medicine","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Animal &amp; Veterinary\u003Cbr>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Michael Wolf\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Compliance Manager and Pharmacist in Charge \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>AHC Products, Inc. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>301 W Broadway St\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Winchester\u003C\u002Fspan>, \u003Cspan>KY\u003C\u002Fspan> \u003Cspan>40391-1915\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Veterinary Medicine\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>June 12, 2026\u003C\u002Fp>\u003Cp>CMS Case: 728604\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Dear Mr. Wolf:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, AHC Products, Inc., located at 301 W Broadway St, Winchester, KY from October 20 to 23, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of FDA’s Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21, Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) [21 U.S.C. § 351(a)(2)(B)].\u003C\u002Fp>\u003Cp>In addition, this letter concerns your firm’s marketing of several unapproved new animal drugs in violation of the Federal Food Drug and Cosmetic Act (FD&amp;C Act). The specific products include \u003Cstrong>(b)(4)\u003C\u002Fstrong>, AniPrin P, and Rot-B-Gone.\u003C\u002Fp>\u003Cp>\u003Cstrong>Current Good Manufacturing Practice Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We reviewed your November 13, 2025, response to our Form FDA 483 in detail. We have not received any other correspondence from you regarding the inspection.\u003C\u002Fp>\u003Cp>Our review of the evidence gathered during the inspection and your response revealed significant violations, including the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm manufactures drug products, including \u003Cstrong>(b)(4)\u003C\u002Fstrong> wound dressing and Animed AniPrin liquid and powder aspirin products (AniPrin LQ and AniPrin P). Your firm failed to ensure that testing and release of drug products for distribution included appropriate laboratory determination of satisfactory conformance to final specifications prior to release. For example, your firm released \u003Cstrong>(b)(4)\u003C\u002Fstrong> lots of \u003Cstrong>(b)(4)\u003C\u002Fstrong> without conducting any finished product laboratory testing. Your firm's product release decisions for these lots were based solely on visual assessment of \u003Cstrong>(b)(4)\u003C\u002Fstrong> properties. Additionally, your firm listed test results for microbiological hazards and heavy metal content on Certificates of Analysis (COAs) for all manufactured lots of AniPrin F, AniPrin LQ, AniPrin LQ with Caffeine, and AniPrin P without performing the corresponding analytical testing on the finished product batches.\u003C\u002Fp>\u003Cp>In your response, you stated that for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, the methodology utilized for product release was color comparison to the original \u003Cstrong>(b)(4)\u003C\u002Fstrong> product, and you referenced a scientific publication suggesting that \u003Cstrong>(b)(4)\u003C\u002Fstrong> concentration can be reliably estimated by color comparison. You indicated that as part of your investigation, you are investigating a \u003Cstrong>(b)(4)\u003C\u002Fstrong> methodology and have preliminarily confirmed through ICP-MS testing that the finished product was approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong>% of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> raw material. You stated that you are in contact with laboratories to conduct USP testing of the raw material and then validation of methodologies to determine conformance of the finished product to final specifications prior to release.\u003C\u002Fp>\u003Cp>Regarding the AniPrin products, you stated that the heavy metal specifications and microbiological specifications listed on your COAs are controlled using incoming raw material specifications with random verification. You indicated that COAs for aspirin products will be revised to remove these specifications, and COAs for other products will be modified to clarify that these specifications are controlled by incoming specifications with random verification.\u003C\u002Fp>\u003Cp>Your response is inadequate. Visual color comparison is a subjective, qualitative assessment that cannot provide quantitative measurement of active ingredient concentration, as color can be affected by many factors including observer subjectivity. The scientific publication you referenced in the response describes a \u003Cstrong>(b)(4)\u003C\u002Fstrong> method for determining \u003Cstrong>(b)(4)\u003C\u002Fstrong> values in \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which is an entirely different matrix, application, and analytical purpose than your \u003Cstrong>(b)(4)\u003C\u002Fstrong> product. You conducted preliminary ICP-MS testing, but the laboratory report you provided in the response explicitly states that \"the methodology employed was not validated for the matrix\" and that \"the variability of the results are likely from an inconsistent dissociation of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and cannot be relied upon to determine a quantitative value for \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\"\u003C\u002Fp>\u003Cp>Related to the AniPrin products, your explanation that microbiological and heavy metal specifications are \"controlled using incoming raw material specifications with random verification\" is insufficient, and your proposed corrective action to simply remove these specifications from your Certificates of Analysis or add clarifying language does not address the underlying compliance issue.\u003C\u002Fp>\u003Cp>You are required to establish appropriate and scientifically-sound specifications for your drug products and then to conduct appropriate laboratory testing for conformance to those specifications. See, e.g., 21 CFR 201.22, 211.160, and 211.165.\u003C\u002Fp>\u003Cp>Moreover, your response lacks a definitive timeline for implementing validated analytical methods, provides no plan for verifying the quality of the product lots already distributed to commerce, and does not include a risk assessment for animals that may have received this inadequately tested product.\u003C\u002Fp>\u003Cp>Release testing is a critical safeguard that verifies the identity, strength, quality, and purity of drug product batches before they reach the end-user. Without appropriate testing protocols in place, defective products that could cause harm may fail to be identified and rejected.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\u003Cli>Procedure(s) describing how your firm maintains drug product retains (reserve samples) for each batch manufactured at your facility.\u003C\u002Fli>\u003Cli>A list of chemical and microbial specifications, including test methods, used to analyze each batch of your drug products before a batch disposition decision.\u003Cbr>o An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\u003Cbr>o A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003C\u002Fli>\u003Cli>The firm name, address, and supplier qualification report for the third-party laboratory or laboratories conducting your drug product release testing.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality (21 CFR 211.84(d)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm failed to ensure that components were suitable for use in the manufacturing of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> product. For example, you did not perform identity testing on each lot of incoming components including the active ingredient \u003Cstrong>(b)(4)\u003C\u002Fstrong> or the inactive ingredients \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>Adequate testing is essential for establishing that raw materials—including, but not limited to, active pharmaceutical ingredients—conform to the appropriate specifications prior to their use in drug product manufacturing, including identity testing to detect potential mix-ups that occurred before you received the components. As a manufacturer, you bear the responsibility of sampling, testing, and examining drug components before releasing them for use in production to ensure that adequate quality standards are met.\u003C\u002Fp>\u003Cp>Your response stated that you sent samples of the active ingredient \u003Cstrong>(b)(4)\u003C\u002Fstrong> along with final product lots for ICP-MS testing and were able to confirm through ICP-MS that the final product was approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong>% of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> raw material. You indicated that you are pursuing USP testing of the raw material with a GMP laboratory, which you expect to be completed within ninety (90) days. You further stated that once you are able to confirm the ability of a GMP laboratory to conduct testing of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> raw material, it will fall under your existing SOP titled \"Quality Testing of Documented Raw Materials.\"\u003C\u002Fp>\u003Cp>Your response is inadequate. The ICP-MS testing you describe was conducted retrospectively, after the raw materials had already been incorporated into finished product that was released and distributed into commerce. You did not describe any interim controls or testing procedures that will be implemented immediately to verify component identity while you establish a relationship with a qualified laboratory. Your response also fails to address the inactive ingredients \u003Cstrong>(b)(4)\u003C\u002Fstrong>, providing no information about whether identity testing will be performed on these components or whether they will continue to be accepted based solely on supplier COAs.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent review of your material system, including but not limited to:\u003Cbr>o evaluating all suppliers of materials (components, containers, and closures) to determine if they are reliable and appropriately qualified;\u003Cbr>o an assessment of all materials to determine whether they are consistently of acceptable quality;\u003Cbr>o a review to ensure assigned expiration or retest dates are appropriate (supported by data);\u003Cbr>o adequacy of the supplier qualification program, and its selection, qualification, and disqualification provisions.\u003C\u002Fli>\u003Cli>Based on a thorough review, provide a summary of your systems corrective action and preventive action (CAPA) to remediate the supplier qualification program and prevent use of unsuitable components, containers and closures.\u003C\u002Fli>\u003Cli>The chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing.\u003C\u002Fli>\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your suppliers’ COAs instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\u003C\u002Fli>\u003Cli>A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your SOP that describes this COA validation program.\u003C\u002Fli>\u003Cli>A summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\u003C\u002Fli>\u003Cli>The firm name, address, and supplier qualification report, for your third-party laboratory or laboratories conducting your raw material testing.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm failed to qualify the equipment and to validate the processes used to manufacture your \u003Cstrong>(b)(4)\u003C\u002Fstrong> product batches, prior to their use in commercial production.\u003C\u002Fp>\u003Cp>Multiple lots of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, a \u003Cstrong>(b)(4)\u003C\u002Fstrong> agent for wounds, cuts, ulcers, and similar conditions, were released to the market since August 2025 without performing process validation to demonstrate a reproducible commercial manufacturing process that yields a product consistently meeting predetermined specifications and quality attributes.\u003C\u002Fp>\u003Cp>Process validation evaluates the design integrity and state of control of a manufacturing process throughout its lifecycle. Each significant manufacturing stage must be appropriately designed to ensure the quality of inputs, in-process materials, and finished products. Process qualification studies establish whether an initial state of control has been achieved and must be successfully completed before commercial distribution. Ongoing monitoring of process performance and product quality is then required to maintain a stable manufacturing operation over the product lifecycle.\u003C\u002Fp>\u003Cp>You responded that you are investigating the initiation of the manufacturing process of the finished product \u003Cstrong>(b)(4)\u003C\u002Fstrong> without adequate validation as part of deviation PDP-769U. You indicated that validation was initiated, and the management team was retrained on the relevant SOP. Your response states that as part of the validation, \u003Cstrong>(b)(4)\u003C\u002Fstrong> lots of \u003Cstrong>(b)(4)\u003C\u002Fstrong> produced since August were tested by ICP-MS to determine the concentration of \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Further, you indicated that with ICP-MS testing, you were able to confirm that the final product was approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong>% of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> raw material.\u003C\u002Fp>\u003Cp>Regarding the equipment qualification, your response was that a deviation (PDP-769U) to SOP PRO-0002.4 Process Change Control has been initiated and that as part of this deviation, you will investigate the implementation of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> (ID \u003Cstrong>(b)(4)\u003C\u002Fstrong>). Additionally, you indicated that as part of the qualification of the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, a \u003Cstrong>(b)(4)\u003C\u002Fstrong> to measure the rate of \u003Cstrong>(b)(4)\u003C\u002Fstrong> was purchased to determine the rate of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and a certified thermistor to confirm the temperature of \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You stated that SOP PRO-0002.4 Process Change Control will be revised.\u003C\u002Fp>\u003Cp>Your response is inadequate because it fails to demonstrate an understanding of process and equipment validation requirements and does not provide a comprehensive plan to validate your manufacturing process or to verify the quality of products already distributed to commerce.\u003C\u002Fp>\u003Cp>The equipment qualification plan included in the response is incomplete. While you state that you have purchased a \u003Cstrong>(b)(4)\u003C\u002Fstrong> and NIST-certified thermistor, merely purchasing measurement instruments does not constitute equipment qualification. You failed to provide a comprehensive qualification protocol to demonstrate that the equipment consistently performs as intended when manufacturing actual product batches.\u003C\u002Fp>\u003Cp>The response did not include a validation protocol that defines for example, the number of validation batches to be manufactured, the sampling plans, the analytical methods to be used with appropriate validation, or the statistical approaches for evaluating process capability.\u003C\u002Fp>\u003Cp>The response addresses only analytical testing of finished products — one component of validation — but fails to address validation of the manufacturing process itself. Using ICP-MS testing on finished product lots as evidence of process validation is scientifically flawed and unacceptable.\u003C\u002Fp>\u003Cp>The ICP-MS results you provided show significant variability, with \u003Cstrong>(b)(4)\u003C\u002Fstrong> concentrations ranging from \u003Cstrong>(b)(4)\u003C\u002Fstrong>% across the \u003Cstrong>(b)(4)\u003C\u002Fstrong> lots tested, representing more than \u003Cstrong>(b)(4) \u003C\u002Fstrong>fold difference. This variability demonstrates that your manufacturing process is not in a state of control and raises questions about whether your products consistently meet the labeled claim of \u003Cstrong>(b)(4)\u003C\u002Fstrong> (equivalent to \u003Cstrong>(b)(4)\u003C\u002Fstrong>% available \u003Cstrong>(b)(4)\u003C\u002Fstrong>). Despite this data, your response provides no explanation for this variability, no investigation into the root causes, and no assessment of whether this variability represents actual differences in product composition or limitations of the analytical method.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>An assessment of each drug product process to ensure that there is a data-driven and scientifically sound program that identifies and controls all sources of variability, such that your production processes will consistently meet appropriate specifications and manufacturing standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, sufficiency of detectability in your monitoring and testing systems, quality of input materials, and reliability of each manufacturing process step and control.\u003C\u002Fli>\u003Cli>A timeline for performing process performance qualification (PPQ) for each of your marketed drug products. Also provide a risk assessment and any follow-up actions to be taken for the distributed drug products produced without performing any process validation studies.\u003C\u002Fli>\u003Cli>Process performance protocol(s), and written procedures for qualification of equipment and facilities.\u003C\u002Fli>\u003Cli>A detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control throughout the product lifecycle. Also, include your program for qualification of your equipment and facility.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment of your in-process monitoring and sampling operations, focusing on each upstream process step that can introduce variability. Provide your remediation plan to improve: (1) upstream process controls; (2) in-process detection of variation; and (3) sampling plans.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>4. Your firm failed to follow your written stability testing program (21 CFR 211.166 (a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm has not initiated stability testing to establish appropriate storage conditions and expiration dating for \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You manufactured and distributed multiple lots of \u003Cstrong>(b)(4)\u003C\u002Fstrong> that did not bear an expiration date in the product label.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Furthermore, stability samples for the following drug products were not tested at the required intervals, and no deviation investigation was initiated: (1) AniPrin P, Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, manufacture date \u003Cstrong>(b)(4)\u003C\u002Fstrong>, missed the \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing which was required on \u003Cstrong>(b)(4)\u003C\u002Fstrong>; and (2) AniPrin LQ 12% Regular Gallon, Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, manufacture date \u003Cstrong>(b)(4)\u003C\u002Fstrong>, missed the \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing which was required on \u003Cstrong>(b)(4)\u003C\u002Fstrong>. This is a repeated observation from the previous inspection conducted in March 2022, where similar deficiencies in your stability program were cited.\u003C\u002Fp>\u003Cp>Stability testing is essential to establish scientifically justified expiration dates and appropriate storage conditions that ensure drug products remain safe and effective from the time of manufacture until the end of their labeled shelf life.\u003C\u002Fp>\u003Cp>Regarding the lack of stability testing for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, your response states that at such time as you are able to establish appropriate testing of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> content of the product, you will add this to your ongoing stability program. You indicated that once you go forward with production, an expiration date will reflect what you find on stability testing the initial lots (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong> months, depending on the testing).\u003C\u002Fp>\u003Cp>Regarding the missed stability testing intervals for AniPrin products, you stated that for AniPrin P, Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, the date the missed \u003Cstrong>(b)(4)\u003C\u002Fstrong> sample was required to be tested should be \u003Cstrong>(b)(4)\u003C\u002Fstrong>, not \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and that the stability samples for this lot were pulled prior to the previous FDA inspection.\u003C\u002Fp>\u003Cp>You indicated that in response to the previous inspection, SOP QUA 00019 was changed to pull an additional two samples so that an extra sample is available if one is damaged, and that a deviation has been initiated. For AniPrin LQ 12% Regular Gallon, Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, you stated that a \u003Cstrong>(b)(4)\u003C\u002Fstrong> stability sample for this lot was not sent and that a deviation was initiated. You stated that the SOP was updated to include a double check that all samples on the reminder system are included in the laboratory accession form and shipped and that the managers responsible were retrained.\u003C\u002Fp>\u003Cp>Your response is inadequate. The response does not address the lack of expiration dates on distributed \u003Cstrong>(b)(4)\u003C\u002Fstrong> products. It does not describe in detail your stability plan with defined stability conditions, time points, and testing of the appropriate critical quality attributes for drug stability, including but not limited to microbiological and impurity testing. Further, you did not include a comprehensive review of all stability samples to verify that no other missed time points exist and failed to describe how you will verify that your revised procedures are effective in preventing recurrence.\u003C\u002Fp>\u003Cp>The requirement to establish a stability program is not contingent upon your ability to develop analytical methods; rather, you should not manufacture and distribute a drug product until you have the capability to conduct appropriate stability testing.\u003C\u002Fp>\u003Cp>Expiration dating must be based on adequate stability data generated under appropriate storage.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\u003Cbr>o Stability indicating methods\u003Cbr>o Stability studies for each drug product in its marketed container-closure system before distribution is permitted\u003Cbr>o An ongoing program in which representative batches of each product are added each \u003Cstrong>(b)(4)\u003C\u002Fstrong> to the program to determine if the shelf-life claim remains valid\u003Cbr>o Detailed definition of the specific attributes to be tested at each station (timepoint)\u003Cbr>o All procedures that describe these and other elements of your remediated stability program.\u003C\u002Fli>\u003Cli>The current expiry date for your finished drug products.\u003C\u002Fli>\u003Cli>The firm name, address, and supplier qualification report for the third-party laboratory or laboratories conducting your drug product stability testing.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Unapproved New Animal Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on our review of your product labeling, your products are drugs under section 201(g)(1) of the Federal Food Drug and Cosmetic Act (FD&amp;C Act) [21 U.S.C. § 321(g)(1)], because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals and\u002For intended to affect the structure or any function of the body of an animal. For the reasons described below, these products are unapproved new animal drugs and introducing or delivering these products for introduction into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\u003Cp>Examples of claims FDA observed on your product labeling that show the intended use of your products as drugs include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cul>\u003Cli>\"\u003Cstrong>(b)(4)\u003C\u002Fstrong>.\"\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>AniPrin P\u003C\u002Fstrong>\u003C\u002Fp>\u003Cul>\u003Cli>“Aids in relieving minor muscle and joint pain.”\u003C\u002Fli>\u003Cli>“…an aid in reducing fever”\u003C\u002Fli>\u003Cli>“…relief of minor muscle aches… pains in horses.”\u003C\u002Fli>\u003Cli>“…Reproductive Harm…”\u003C\u002Fli>\u003Cli>“...analgesic”\u003C\u002Fli>\u003Cli>“...antipyretic”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Rot-B-Gone\u003C\u002Fstrong>\u003C\u002Fp>\u003Cul>\u003Cli>“...If redness, irritation,..swelling persist, discontinue use.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your products are new animal drugs under section 201(v) of the FD&amp;C Act, [21 U.S.C. § 321(v)], because they are not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling.\u003C\u002Fp>\u003Cp>To be legally marketed, a new animal drug must have an approved new animal drug application, conditionally approved new animal drug application, or index listing under sections 512, 571, and 572 of the FD&amp;C Act [21 U.S.C. § 360b, 360ccc, and 360ccc-1]. These products are not approved or index listed by FDA, and therefore, the products are unsafe within the meaning of section 512(a) of the FD&amp;C Act, [21 U.S.C. § 360b(a)], and adulterated under section 501(a)(5) of the FD&amp;C Act [21 U.S.C. § 351(a)(5)]. The introduction or delivery for introduction into interstate commerce of an adulterated drug is prohibited under section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>You must correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice, including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you with an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CVM-483-Responses@fda.hhs.gov. Refer to the CMS Case number 728604 FEI 3002745172 and ATTN: Dayna I. Martínez when replying.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Johnetta Walters, Ph.D.\u003Cbr>Acting Director\u003Cbr>Division of Drug Compliance\u003Cbr>Office Surveillance and Compliance\u003Cbr>Center for Veterinary Medicine\u003C\u002Fp>\u003Cp>___________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> See also, 21 CFR 211.137.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> i.e., Quality System, Facilities &amp; Equipment System, Materials System, Production System, Packaging &amp; Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nAnimal & Veterinary\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Michael Wolf\n\nRecipient Title\n\nCompliance Manager and Pharmacist in Charge\n\nAHC Products, Inc.\n\n301 W Broadway St\n\nWinchester, KY 40391-1915\n\nUnited States\n\nIssuing Office:\n\nCenter for Veterinary Medicine\n\nUnited States\n\nJune 12, 2026\nCMS Case: 728604\nWARNING LETTER\nDear Mr. Wolf:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, AHC Products, Inc., located at 301 W Broadway St, Winchester, KY from October 20 to 23, 2025.\nThis warning letter summarizes significant violations of FDA’s Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21, Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. § 351(a)(2)(B)].\nIn addition, this letter concerns your firm’s marketing of several unapproved new animal drugs in violation of the Federal Food Drug and Cosmetic Act (FD&C Act). The specific products include (b)(4), AniPrin P, and Rot-B-Gone.\nCurrent Good Manufacturing Practice Violations\nWe reviewed your November 13, 2025, response to our Form FDA 483 in detail. We have not received any other correspondence from you regarding the inspection.\nOur review of the evidence gathered during the inspection and your response revealed significant violations, including the following.\n1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\nYour firm manufactures drug products, including (b)(4) wound dressing and Animed AniPrin liquid and powder aspirin products (AniPrin LQ and AniPrin P). Your firm failed to ensure that testing and release of drug products for distribution included appropriate laboratory determination of satisfactory conformance to final specifications prior to release. For example, your firm released (b)(4) lots of (b)(4) without conducting any finished product laboratory testing. Your firm's product release decisions for these lots were based solely on visual assessment of (b)(4) properties. Additionally, your firm listed test results for microbiological hazards and heavy metal content on Certificates of Analysis (COAs) for all manufactured lots of AniPrin F, AniPrin LQ, AniPrin LQ with Caffeine, and AniPrin P without performing the corresponding analytical testing on the finished product batches.\nIn your response, you stated that for (b)(4), the methodology utilized for product release was color comparison to the original (b)(4) product, and you referenced a scientific publication suggesting that (b)(4) concentration can be reliably estimated by color comparison. You indicated that as part of your investigation, you are investigating a (b)(4) methodology and have preliminarily confirmed through ICP-MS testing that the finished product was approximately (b)(4)% of the (b)(4) raw material. You stated that you are in contact with laboratories to conduct USP testing of the raw material and then validation of methodologies to determine conformance of the finished product to final specifications prior to release.\nRegarding the AniPrin products, you stated that the heavy metal specifications and microbiological specifications listed on your COAs are controlled using incoming raw material specifications with random verification. You indicated that COAs for aspirin products will be revised to remove these specifications, and COAs for other products will be modified to clarify that these specifications are controlled by incoming specifications with random verification.\nYour response is inadequate. Visual color comparison is a subjective, qualitative assessment that cannot provide quantitative measurement of active ingredient concentration, as color can be affected by many factors including observer subjectivity. The scientific publication you referenced in the response describes a (b)(4) method for determining (b)(4) values in (b)(4), which is an entirely different matrix, application, and analytical purpose than your (b)(4) product. You conducted preliminary ICP-MS testing, but the laboratory report you provided in the response explicitly states that \"the methodology employed was not validated for the matrix\" and that \"the variability of the results are likely from an inconsistent dissociation of the (b)(4) and cannot be relied upon to determine a quantitative value for (b)(4).\"\nRelated to the AniPrin products, your explanation that microbiological and heavy metal specifications are \"controlled using incoming raw material specifications with random verification\" is insufficient, and your proposed corrective action to simply remove these specifications from your Certificates of Analysis or add clarifying language does not address the underlying compliance issue.\nYou are required to establish appropriate and scientifically-sound specifications for your drug products and then to conduct appropriate laboratory testing for conformance to those specifications. See, e.g., 21 CFR 201.22, 211.160, and 211.165.\nMoreover, your response lacks a definitive timeline for implementing validated analytical methods, provides no plan for verifying the quality of the product lots already distributed to commerce, and does not include a risk assessment for animals that may have received this inadequately tested product.\nRelease testing is a critical safeguard that verifies the identity, strength, quality, and purity of drug product batches before they reach the end-user. Without appropriate testing protocols in place, defective products that could cause harm may fail to be identified and rejected.\nIn response to this letter, provide:\nA comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\nProcedure(s) describing how your firm maintains drug product retains (reserve samples) for each batch manufactured at your facility.\nA list of chemical and microbial specifications, including test methods, used to analyze each batch of your drug products before a batch disposition decision.\no An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\no A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\nThe firm name, address, and supplier qualification report for the third-party laboratory or laboratories conducting your drug product release testing.\n2. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality (21 CFR 211.84(d)).\nYour firm failed to ensure that components were suitable for use in the manufacturing of your (b)(4) product. For example, you did not perform identity testing on each lot of incoming components including the active ingredient (b)(4) or the inactive ingredients (b)(4).\nAdequate testing is essential for establishing that raw materials—including, but not limited to, active pharmaceutical ingredients—conform to the appropriate specifications prior to their use in drug product manufacturing, including identity testing to detect potential mix-ups that occurred before you received the components. As a manufacturer, you bear the responsibility of sampling, testing, and examining drug components before releasing them for use in production to ensure that adequate quality standards are met.\nYour response stated that you sent samples of the active ingredient (b)(4) along with final product lots for ICP-MS testing and were able to confirm through ICP-MS that the final product was approximately (b)(4)% of the (b)(4) raw material. You indicated that you are pursuing USP testing of the raw material with a GMP laboratory, which you expect to be completed within ninety (90) days. You further stated that once you are able to confirm the ability of a GMP laboratory to conduct testing of the (b)(4) raw material, it will fall under your existing SOP titled \"Quality Testing of Documented Raw Materials.\"\nYour response is inadequate. The ICP-MS testing you describe was conducted retrospectively, after the raw materials had already been incorporated into finished product that was released and distributed into commerce. You did not describe any interim controls or testing procedures that will be implemented immediately to verify component identity while you establish a relationship with a qualified laboratory. Your response also fails to address the inactive ingredients (b)(4), providing no information about whether identity testing will be performed on these components or whether they will continue to be accepted based solely on supplier COAs.\nIn response to this letter, provide:\nA comprehensive, independent review of your material system, including but not limited to:\no evaluating all suppliers of materials (components, containers, and closures) to determine if they are reliable and appropriately qualified;\no an assessment of all materials to determine whether they are consistently of acceptable quality;\no a review to ensure assigned expiration or retest dates are appropriate (supported by data);\no adequacy of the supplier qualification program, and its selection, qualification, and disqualification provisions.\nBased on a thorough review, provide a summary of your systems corrective action and preventive action (CAPA) to remediate the supplier qualification program and prevent use of unsuitable components, containers and closures.\nThe chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing.\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your suppliers’ COAs instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\nA summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your SOP that describes this COA validation program.\nA summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\nThe firm name, address, and supplier qualification report, for your third-party laboratory or laboratories conducting your raw material testing.\n3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\nYour firm failed to qualify the equipment and to validate the processes used to manufacture your (b)(4) product batches, prior to their use in commercial production.\nMultiple lots of (b)(4), a (b)(4) agent for wounds, cuts, ulcers, and similar conditions, were released to the market since August 2025 without performing process validation to demonstrate a reproducible commercial manufacturing process that yields a product consistently meeting predetermined specifications and quality attributes.\nProcess validation evaluates the design integrity and state of control of a manufacturing process throughout its lifecycle. Each significant manufacturing stage must be appropriately designed to ensure the quality of inputs, in-process materials, and finished products. Process qualification studies establish whether an initial state of control has been achieved and must be successfully completed before commercial distribution. Ongoing monitoring of process performance and product quality is then required to maintain a stable manufacturing operation over the product lifecycle.\nYou responded that you are investigating the initiation of the manufacturing process of the finished product (b)(4) without adequate validation as part of deviation PDP-769U. You indicated that validation was initiated, and the management team was retrained on the relevant SOP. Your response states that as part of the validation, (b)(4) lots of (b)(4) produced since August were tested by ICP-MS to determine the concentration of (b)(4). Further, you indicated that with ICP-MS testing, you were able to confirm that the final product was approximately (b)(4)% of the (b)(4) raw material.\nRegarding the equipment qualification, your response was that a deviation (PDP-769U) to SOP PRO-0002.4 Process Change Control has been initiated and that as part of this deviation, you will investigate the implementation of the (b)(4) (ID (b)(4)). Additionally, you indicated that as part of the qualification of the (b)(4), a (b)(4) to measure the rate of (b)(4) was purchased to determine the rate of (b)(4), and a certified thermistor to confirm the temperature of (b)(4). You stated that SOP PRO-0002.4 Process Change Control will be revised.\nYour response is inadequate because it fails to demonstrate an understanding of process and equipment validation requirements and does not provide a comprehensive plan to validate your manufacturing process or to verify the quality of products already distributed to commerce.\nThe equipment qualification plan included in the response is incomplete. While you state that you have purchased a (b)(4) and NIST-certified thermistor, merely purchasing measurement instruments does not constitute equipment qualification. You failed to provide a comprehensive qualification protocol to demonstrate that the equipment consistently performs as intended when manufacturing actual product batches.\nThe response did not include a validation protocol that defines for example, the number of validation batches to be manufactured, the sampling plans, the analytical methods to be used with appropriate validation, or the statistical approaches for evaluating process capability.\nThe response addresses only analytical testing of finished products — one component of validation — but fails to address validation of the manufacturing process itself. Using ICP-MS testing on finished product lots as evidence of process validation is scientifically flawed and unacceptable.\nThe ICP-MS results you provided show significant variability, with (b)(4) concentrations ranging from (b)(4)% across the (b)(4) lots tested, representing more than (b)(4) fold difference. This variability demonstrates that your manufacturing process is not in a state of control and raises questions about whether your products consistently meet the labeled claim of (b)(4) (equivalent to (b)(4)% available (b)(4)). Despite this data, your response provides no explanation for this variability, no investigation into the root causes, and no assessment of whether this variability represents actual differences in product composition or limitations of the analytical method.\nIn response to this letter, provide:\nAn assessment of each drug product process to ensure that there is a data-driven and scientifically sound program that identifies and controls all sources of variability, such that your production processes will consistently meet appropriate specifications and manufacturing standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, sufficiency of detectability in your monitoring and testing systems, quality of input materials, and reliability of each manufacturing process step and control.\nA timeline for performing process performance qualification (PPQ) for each of your marketed drug products. Also provide a risk assessment and any follow-up actions to be taken for the distributed drug products produced without performing any process validation studies.\nProcess performance protocol(s), and written procedures for qualification of equipment and facilities.\nA detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control throughout the product lifecycle. Also, include your program for qualification of your equipment and facility.\nA comprehensive, independent assessment of your in-process monitoring and sampling operations, focusing on each upstream process step that can introduce variability. Provide your remediation plan to improve: (1) upstream process controls; (2) in-process detection of variation; and (3) sampling plans.\n4. Your firm failed to follow your written stability testing program (21 CFR 211.166 (a)).\nYour firm has not initiated stability testing to establish appropriate storage conditions and expiration dating for (b)(4). You manufactured and distributed multiple lots of (b)(4) that did not bear an expiration date in the product label.1\nFurthermore, stability samples for the following drug products were not tested at the required intervals, and no deviation investigation was initiated: (1) AniPrin P, Lot (b)(4), manufacture date (b)(4), missed the (b)(4) testing which was required on (b)(4); and (2) AniPrin LQ 12% Regular Gallon, Lot (b)(4), manufacture date (b)(4), missed the (b)(4) testing which was required on (b)(4). This is a repeated observation from the previous inspection conducted in March 2022, where similar deficiencies in your stability program were cited.\nStability testing is essential to establish scientifically justified expiration dates and appropriate storage conditions that ensure drug products remain safe and effective from the time of manufacture until the end of their labeled shelf life.\nRegarding the lack of stability testing for (b)(4), your response states that at such time as you are able to establish appropriate testing of the (b)(4) content of the product, you will add this to your ongoing stability program. You indicated that once you go forward with production, an expiration date will reflect what you find on stability testing the initial lots (e.g., (b)(4) months, depending on the testing).\nRegarding the missed stability testing intervals for AniPrin products, you stated that for AniPrin P, Lot (b)(4), the date the missed (b)(4) sample was required to be tested should be (b)(4), not (b)(4), and that the stability samples for this lot were pulled prior to the previous FDA inspection.\nYou indicated that in response to the previous inspection, SOP QUA 00019 was changed to pull an additional two samples so that an extra sample is available if one is damaged, and that a deviation has been initiated. For AniPrin LQ 12% Regular Gallon, Lot (b)(4), you stated that a (b)(4) stability sample for this lot was not sent and that a deviation was initiated. You stated that the SOP was updated to include a double check that all samples on the reminder system are included in the laboratory accession form and shipped and that the managers responsible were retrained.\nYour response is inadequate. The response does not address the lack of expiration dates on distributed (b)(4) products. It does not describe in detail your stability plan with defined stability conditions, time points, and testing of the appropriate critical quality attributes for drug stability, including but not limited to microbiological and impurity testing. Further, you did not include a comprehensive review of all stability samples to verify that no other missed time points exist and failed to describe how you will verify that your revised procedures are effective in preventing recurrence.\nThe requirement to establish a stability program is not contingent upon your ability to develop analytical methods; rather, you should not manufacture and distribute a drug product until you have the capability to conduct appropriate stability testing.\nExpiration dating must be based on adequate stability data generated under appropriate storage.\nIn response to this letter, provide:\nA comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\no Stability indicating methods\no Stability studies for each drug product in its marketed container-closure system before distribution is permitted\no An ongoing program in which representative batches of each product are added each (b)(4) to the program to determine if the shelf-life claim remains valid\no Detailed definition of the specific attributes to be tested at each station (timepoint)\no All procedures that describe these and other elements of your remediated stability program.\nThe current expiry date for your finished drug products.\nThe firm name, address, and supplier qualification report for the third-party laboratory or laboratories conducting your drug product stability testing.\nUnapproved New Animal Drug Violations\nBased on our review of your product labeling, your products are drugs under section 201(g)(1) of the Federal Food Drug and Cosmetic Act (FD&C Act) [21 U.S.C. § 321(g)(1)], because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals and\u002For intended to affect the structure or any function of the body of an animal. For the reasons described below, these products are unapproved new animal drugs and introducing or delivering these products for introduction into interstate commerce is prohibited under section 301(a) of the FD&C Act [21 U.S.C. § 331(a)].\nExamples of claims FDA observed on your product labeling that show the intended use of your products as drugs include, but are not limited to, the following:\n(b)(4)\n\"(b)(4).\"\nAniPrin P\n“Aids in relieving minor muscle and joint pain.”\n“…an aid in reducing fever”\n“…relief of minor muscle aches… pains in horses.”\n“…Reproductive Harm…”\n“...analgesic”\n“...antipyretic”\nRot-B-Gone\n“...If redness, irritation,..swelling persist, discontinue use.”\nYour products are new animal drugs under section 201(v) of the FD&C Act, [21 U.S.C. § 321(v)], because they are not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling.\nTo be legally marketed, a new animal drug must have an approved new animal drug application, conditionally approved new animal drug application, or index listing under sections 512, 571, and 572 of the FD&C Act [21 U.S.C. § 360b, 360ccc, and 360ccc-1]. These products are not approved or index listed by FDA, and therefore, the products are unsafe within the meaning of section 512(a) of the FD&C Act, [21 U.S.C. § 360b(a)], and adulterated under section 501(a)(5) of the FD&C Act [21 U.S.C. § 351(a)(5)]. The introduction or delivery for introduction into interstate commerce of an adulterated drug is prohibited under section 301(a) of the FD&C Act [21 U.S.C. § 331(a)].\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit2 of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nYou must correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice, including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\nThis letter notifies you of our findings and provides you with an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CVM-483-Responses@fda.hhs.gov. Refer to the CMS Case number 728604 FEI 3002745172 and ATTN: Dayna I. Martínez when replying.\nSincerely,\n\u002FS\u002F\nJohnetta Walters, Ph.D.\nActing Director\nDivision of Drug Compliance\nOffice Surveillance and Compliance\nCenter for Veterinary Medicine\n___________________\n1 See also, 21 CFR 211.137.\n2 i.e., Quality System, Facilities & Equipment System, Materials System, Production System, Packaging & Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.","AHC Products, Inc.","ahc-products-inc-728604-06122026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fahc-products-inc-728604-06122026","2026-10-26T08:07:51.4831+00:00","2026-07-28","728604","Animal & VeterinaryDrugs","Mr. Michael Wolf","2026-08-19T04:27:41.535+00:00","VIA Electronic Mail","2026-06-12",{"id":74,"raw":75,"subject":80,"body_html":81,"body_text":82,"firm_name":83,"letter_id":84,"created_at":63,"fei_number":19,"letter_url":85,"updated_at":86,"action_type":22,"case_status":23,"posted_date":87,"marcs_cms_no":88,"product_type":89,"closeout_date":19,"issuing_office":79,"recipient_name":90,"body_fetched_at":91,"delivery_method":92,"recipient_title":19,"reference_number":88,"action_taken_date":93,"medical_device_id":19,"response_letter_date":19},145,[76,77,78,79,80,13,13,13],"\u003Ctime datetime=\"2026-05-26T04:00:00Z\">05\u002F26\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-05-18T04:00:00Z\">05\u002F18\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgsc-products-llc-729653-05182026\">GSC Products, LLC\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","Nonprescription\u002FOTC","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Electronic Mail - Delivery and Read Receipt Requested\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>729653\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Wayne Perry\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Founder and President \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>GSC Products, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1441 Van Patten Rd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Duanesburg\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>12056-2522\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6), (b)(7)(C)\"> (b)(6), (b)(7)(C)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>May 18, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>To Wayne Perry:\u003C\u002Fp>\u003Cp>This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) review of your websites. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>\u003Cstrong>FDA Review\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Violations were identified and documented during a review of your websites, https:\u002F\u002Fsinusplumber.com and https:\u002F\u002Fwww.greensations.com, in March 2026. Your https:\u002F\u002Fsinusplumber.com website also directs consumers to your Amazon storefront to purchase your product. Based on our review, your SINUS PLUMBER Headache Nasal Spray product is an unapproved new drug under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a). In addition, this product is misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). As explained further below, introducing or delivering this product for introduction into interstate commerce is prohibited under sections 301(d) and 301(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 331(a).\u003C\u002Fp>\u003Cp>This review was conducted under FDA’s public health responsibilities to protect the public from unsafe, ineffective, and poor-quality drugs.\u003C\u002Fp>\u003Cp>\u003Cstrong>Violations of the Federal Food, Drug, and Cosmetic Act\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.\u003C\u002Fp>\u003Cp>Based on a review of your websites, your SINUS PLUMBER Headache Nasal Spray is a drug under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples from your product labeling, including your websites, that provide evidence of the intended use (as defined in 21 CFR 201.128) of this product as a drug include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>“\u003Cstrong>Drug Facts . . . Purpose\u003C\u002Fstrong>…Relieves pain and nausea…Relieves pain &amp; inflammation…Increases circulation . . . \u003Cstrong>Uses\u003C\u002Fstrong>: For the temporary relief of: ■ General headache and migraine symptoms.” [from the product label on the Sinus Plumber product website https:\u002F\u002Fsinusplumber.com\u002Fproducts\u002Fsinus-plumber-migraine-headache-nasal-spray-with-capsaicin]\u003C\u002Fp>\u003Cp>“Powerful &amp; Fast Headache Relief √ Tension √ Clusters √ Migraines” [from the product label on the Sinus Plumber product website https:\u002F\u002Fsinusplumber.com\u002Fproducts\u002Fsinus-plumber-migraine-headache-nasal-spray-with-capsaicin and\u003Cbr>https:\u002F\u002Fwww.greensations.com\u002FCayenne-Pepper-Headache-Nasal-Spray-p\u002Fsp-4.htm]\u003C\u002Fp>\u003Cp>“Sinus Plumber Headache Nasal Spray targets a variety of headaches with the pain relief power of capsaicin, feverfew, peppermint and caffeine.”…“This formula is commonly used for headaches that feel sinus-related or pressure-driven, including sinus headaches, tension headaches, migraines, and cluster headaches.” [from the Sinus Plumber product website https:\u002F\u002Fsinusplumber.com\u002Fproducts\u002Fsinus-plumber-migraine-headache-nasal-spray-with-capsaicin and https:\u002F\u002Fwww.greensations.com\u002FCayenne-Pepper-Headache-Nasal-Spray-p\u002Fsp-4.htm]\u003C\u002Fp>\u003Cp>Based on the above labeling evidence, SINUS PLUMBER Headache Nasal Spray is intended for use as an internal analgesic drug product. As described below, this drug product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>A drug product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for this drug product identified above.\u003C\u002Fp>\u003Cp>Under section 505G of the FD&amp;C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as “over-the-counter (OTC) monograph drugs”—may be legally marketed if they meet applicable requirements. With respect to nonprescription internal analgesic drug products, such as your SINUS PLUMBER Headache Nasal Spray, in order to be GRASE and not a new drug, the product must, among other things, conform to the conditions in the applicable OTC monograph, here M013: Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Use (hereinafter “M013”).\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> However, SINUS PLUMBER Headache Nasal Spray does not conform to the conditions specified in M013 for the reasons described below.\u003C\u002Fp>\u003Cp>Your SINUS PLUMBER Headache Nasal Spray is intended to be applied inside the nostrils. Under M013.1, only an OTC internal analgesic drug product in a form suitable for oral administration is generally recognized as safe and effective if it meets the conditions of M013. Thus, your internal analgesic drug product intended for administration inside the nostrils, does not conform to the conditions of M013.\u003C\u002Fp>\u003Cp>In addition, your SINUS PLUMBER Headache Nasal Spray labeling includes intended uses that are not permitted for OTC internal analgesic drug products in M013. Specifically, claims such as “This formula is commonly used for headaches that feel sinus-related or pressure-driven, including sinus headaches, tension headaches, migraines, and cluster headaches.” and “Purpose . . . Relieves . . . nausea . . . inflammation . . . increase circulation” that suggest SINUS PLUMBER Headache Nasal Spray is intended to treat sinuses, tension, clusters, and migraines, and is intended to relieve nausea, inflammation, and increase circulation go beyond the general intended uses for an OTC internal analgesic drug product and do not conform to the permitted uses set forth in M013.50(b).\u003C\u002Fp>\u003Cp>Furthermore, your SINUS PLUMBER Headache Nasal Spray is formulated with active ingredients that are not permitted for OTC internal analgesic drug products under M013.10. Specifically, feverfew, arnica montana, oleoresin capsicum, caffeine anhydrous, and peppermint oil are not permitted as single active ingredients under M013.10, nor is this combination of active ingredients permitted under M013.20. Therefore, your SINSUS PLUMBER Headache Nasal Spray product does not conform with the conditions for lawful marketing of an OTC internal analgesic drug product as set forth in M013.\u003C\u002Fp>\u003Cp>Thus, your SINUS PLUMBER Headache Nasal Spray product does not comply with the applicable conditions specified in M013 and has not otherwise been found GRASE.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Accordingly, this product is a new drug within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), and there is no basis under section 505G of the FD&amp;C Act under which this product would be legally marketed without an approved application. Because there is no approved application in effect for this product, this product is an unapproved new drug.\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction into interstate commerce of this unapproved new drug product violates sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>\u003Cstrong>Misbranded Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Additionally, SINUS PLUMBER Headache Nasal Spray is misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because this product is a nonprescription drug subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>As previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future compliance so that these violations and any others do not occur.\u003C\u002Fp>\u003Cp>Send your written response to FDAAdvisory@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. Identify your response with reference number “729653” in the subject line of the email.\u003C\u002Fp>\u003Cp>If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration.\u003C\u002Fp>\u003Cp>Please note FDA posts warning letters on www.fda.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs and Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>_______________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> M013 reflects the conditions as set forth in the relevant final orders established and in effect under section 505G; see Order OTC000027, available at FDA’s website OTC Monographs@FDA [https:\u002F\u002Fdps.fda.gov\u002Fomuf]\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that SINUS PLUMBER Headache Nasal Spray is GRASE for use under the conditions prescribed, recommended, or suggested in its labeling, nor has FDA determined this drug product to be GRASE pursuant to an order issued under section 505G(b).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Electronic Mail - Delivery and Read Receipt Requested\n\nReference #:\n\n729653\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nWayne Perry\n\nRecipient Title\n\nFounder and President\n\nGSC Products, LLC\n\n1441 Van Patten Rd\n\nDuanesburg, NY 12056-2522\n\nUnited States\n\n(b)(6), (b)(7)(C)\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nMay 18, 2026\nWARNING LETTER\nTo Wayne Perry:\nThis warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) review of your websites. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.\nFDA Review\nViolations were identified and documented during a review of your websites, https:\u002F\u002Fsinusplumber.com and https:\u002F\u002Fwww.greensations.com, in March 2026. Your https:\u002F\u002Fsinusplumber.com website also directs consumers to your Amazon storefront to purchase your product. Based on our review, your SINUS PLUMBER Headache Nasal Spray product is an unapproved new drug under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). In addition, this product is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). As explained further below, introducing or delivering this product for introduction into interstate commerce is prohibited under sections 301(d) and 301(a) of the FD&C Act, 21 U.S.C. 331(d) and 331(a).\nThis review was conducted under FDA’s public health responsibilities to protect the public from unsafe, ineffective, and poor-quality drugs.\nViolations of the Federal Food, Drug, and Cosmetic Act\nUnapproved New Drug Violations\nThe following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.\nBased on a review of your websites, your SINUS PLUMBER Headache Nasal Spray is a drug under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples from your product labeling, including your websites, that provide evidence of the intended use (as defined in 21 CFR 201.128) of this product as a drug include, but may not be limited to, the following:\n“Drug Facts . . . Purpose…Relieves pain and nausea…Relieves pain & inflammation…Increases circulation . . . Uses: For the temporary relief of: ■ General headache and migraine symptoms.” [from the product label on the Sinus Plumber product website https:\u002F\u002Fsinusplumber.com\u002Fproducts\u002Fsinus-plumber-migraine-headache-nasal-spray-with-capsaicin]\n“Powerful & Fast Headache Relief √ Tension √ Clusters √ Migraines” [from the product label on the Sinus Plumber product website https:\u002F\u002Fsinusplumber.com\u002Fproducts\u002Fsinus-plumber-migraine-headache-nasal-spray-with-capsaicin and\nhttps:\u002F\u002Fwww.greensations.com\u002FCayenne-Pepper-Headache-Nasal-Spray-p\u002Fsp-4.htm]\n“Sinus Plumber Headache Nasal Spray targets a variety of headaches with the pain relief power of capsaicin, feverfew, peppermint and caffeine.”…“This formula is commonly used for headaches that feel sinus-related or pressure-driven, including sinus headaches, tension headaches, migraines, and cluster headaches.” [from the Sinus Plumber product website https:\u002F\u002Fsinusplumber.com\u002Fproducts\u002Fsinus-plumber-migraine-headache-nasal-spray-with-capsaicin and https:\u002F\u002Fwww.greensations.com\u002FCayenne-Pepper-Headache-Nasal-Spray-p\u002Fsp-4.htm]\nBased on the above labeling evidence, SINUS PLUMBER Headache Nasal Spray is intended for use as an internal analgesic drug product. As described below, this drug product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d).\nA drug product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for this drug product identified above.\nUnder section 505G of the FD&C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as “over-the-counter (OTC) monograph drugs”—may be legally marketed if they meet applicable requirements. With respect to nonprescription internal analgesic drug products, such as your SINUS PLUMBER Headache Nasal Spray, in order to be GRASE and not a new drug, the product must, among other things, conform to the conditions in the applicable OTC monograph, here M013: Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Use (hereinafter “M013”).1 However, SINUS PLUMBER Headache Nasal Spray does not conform to the conditions specified in M013 for the reasons described below.\nYour SINUS PLUMBER Headache Nasal Spray is intended to be applied inside the nostrils. Under M013.1, only an OTC internal analgesic drug product in a form suitable for oral administration is generally recognized as safe and effective if it meets the conditions of M013. Thus, your internal analgesic drug product intended for administration inside the nostrils, does not conform to the conditions of M013.\nIn addition, your SINUS PLUMBER Headache Nasal Spray labeling includes intended uses that are not permitted for OTC internal analgesic drug products in M013. Specifically, claims such as “This formula is commonly used for headaches that feel sinus-related or pressure-driven, including sinus headaches, tension headaches, migraines, and cluster headaches.” and “Purpose . . . Relieves . . . nausea . . . inflammation . . . increase circulation” that suggest SINUS PLUMBER Headache Nasal Spray is intended to treat sinuses, tension, clusters, and migraines, and is intended to relieve nausea, inflammation, and increase circulation go beyond the general intended uses for an OTC internal analgesic drug product and do not conform to the permitted uses set forth in M013.50(b).\nFurthermore, your SINUS PLUMBER Headache Nasal Spray is formulated with active ingredients that are not permitted for OTC internal analgesic drug products under M013.10. Specifically, feverfew, arnica montana, oleoresin capsicum, caffeine anhydrous, and peppermint oil are not permitted as single active ingredients under M013.10, nor is this combination of active ingredients permitted under M013.20. Therefore, your SINSUS PLUMBER Headache Nasal Spray product does not conform with the conditions for lawful marketing of an OTC internal analgesic drug product as set forth in M013.\nThus, your SINUS PLUMBER Headache Nasal Spray product does not comply with the applicable conditions specified in M013 and has not otherwise been found GRASE.2 Accordingly, this product is a new drug within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), and there is no basis under section 505G of the FD&C Act under which this product would be legally marketed without an approved application. Because there is no approved application in effect for this product, this product is an unapproved new drug.\nThe introduction or delivery for introduction into interstate commerce of this unapproved new drug product violates sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d).\nMisbranded Drug Violations\nAdditionally, SINUS PLUMBER Headache Nasal Spray is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because this product is a nonprescription drug subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\nConclusion\nAs previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future compliance so that these violations and any others do not occur.\nSend your written response to FDAAdvisory@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. Identify your response with reference number “729653” in the subject line of the email.\nIf you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration.\nPlease note FDA posts warning letters on www.fda.gov.\nSincerely,\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs and Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n_______________________\n1 M013 reflects the conditions as set forth in the relevant final orders established and in effect under section 505G; see Order OTC000027, available at FDA’s website OTC Monographs@FDA [https:\u002F\u002Fdps.fda.gov\u002Fomuf]\n2 FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that SINUS PLUMBER Headache Nasal Spray is GRASE for use under the conditions prescribed, recommended, or suggested in its labeling, nor has FDA determined this drug product to be GRASE pursuant to an order issued under section 505G(b).","GSC Products, LLC","gsc-products-llc-729653-05182026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgsc-products-llc-729653-05182026","2026-10-26T08:08:50.940349+00:00","2026-05-26","729653","Drugs Over-the-Counter Drugs","Wayne Perry","2026-08-19T04:39:54.735+00:00","Via Electronic Mail - Delivery and Read Receipt Requested","2026-05-18",{"id":95,"raw":96,"subject":101,"body_html":102,"body_text":103,"firm_name":104,"letter_id":105,"created_at":106,"fei_number":19,"letter_url":107,"updated_at":108,"action_type":22,"case_status":23,"posted_date":109,"marcs_cms_no":110,"product_type":111,"closeout_date":19,"issuing_office":100,"recipient_name":19,"body_fetched_at":112,"delivery_method":113,"recipient_title":19,"reference_number":114,"action_taken_date":115,"medical_device_id":19,"response_letter_date":19},546,[97,98,99,100,101,13,13,13],"\u003Ctime datetime=\"2025-10-07T04:00:00Z\">10\u002F07\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-10-02T04:00:00Z\">10\u002F02\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flbc-products-inc-717608-10022025\">LBC Products Inc.\u003C\u002Fa>","Center for Tobacco Products","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>ER2501315\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>LBC Products Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>6360 South Pecos Road, Suite 8\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Las Vegas\u003C\u002Fspan>, \u003Cspan>NV\u003C\u002Fspan> \u003Cspan>89120\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:lehab@lbcproducts.com\"> lehab@lbcproducts.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>October 2, 2025\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>To Whom It May Concern:\u003C\u002Fp>\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed our inspection records and determined that LBC PRODUCTS INC. sells and\u002For distributes e-liquid products to customers in the United States.\u003C\u002Fp>\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including e-liquid products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\u003C\u002Fp>\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has determined that you offer for sale or distribution to customers in the United States the following e-liquid products that lack a marketing authorization order: HUSTLER PREMIUM E-LIQUID STRAWBERRY BLONDE 60 ML 3MG\u002FML.\u003C\u002Fp>\u003Cp>The tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\u003Cp>For a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\u003C\u002Fp>\u003Cp>It is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq. or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, or 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above and take any necessary actions to bring these tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that these products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\u003Cp>Please note your reference number, ER2501315, in your response and direct your response to the following address:\u003C\u002Fp>\u003Cp>DEM-WL Response, Office of Compliance and Enforcement&nbsp;&nbsp;\u003Cbr>FDA Center for Tobacco Products&nbsp;&nbsp;\u003Cbr>c\u002Fo Document Control Center&nbsp;&nbsp;\u003Cbr>Building 71, Room G335&nbsp;&nbsp;\u003Cbr>10903 New Hampshire Avenue&nbsp;&nbsp;\u003Cbr>Silver Spring, MD 20993-0002\u003C\u002Fp>\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003Cbr>John E. Verbeten\u003Cbr>Director\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Center for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nER2501315\n\nProduct:\n\nTobacco\n\nRecipient:\n\nLBC Products Inc.\n\n6360 South Pecos Road, Suite 8\n\nLas Vegas, NV 89120\n\nUnited States\n\nlehab@lbcproducts.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nOctober 2, 2025\nWARNING LETTER\nTo Whom It May Concern:\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed our inspection records and determined that LBC PRODUCTS INC. sells and\u002For distributes e-liquid products to customers in the United States.\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including e-liquid products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\nNew Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\nFDA has determined that you offer for sale or distribution to customers in the United States the following e-liquid products that lack a marketing authorization order: HUSTLER PREMIUM E-LIQUID STRAWBERRY BLONDE 60 ML 3MG\u002FML.\nThe tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&C Act.\nConclusion and Requested Actions\nFDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\nFor a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\nIt is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq. or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, or 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above and take any necessary actions to bring these tobacco products into compliance with the FD&C Act.\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that these products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\nPlease note your reference number, ER2501315, in your response and direct your response to the following address:\nDEM-WL Response, Office of Compliance and Enforcement\nFDA Center for Tobacco Products\nc\u002Fo Document Control Center\nBuilding 71, Room G335\n10903 New Hampshire Avenue\nSilver Spring, MD 20993-0002\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nJohn E. Verbeten\nDirector\nOffice of Compliance and Enforcement\nCenter for Tobacco Products","LBC Products Inc.","lbc-products-inc-717608-10022025","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flbc-products-inc-717608-10022025","2026-10-26T08:09:12.826898+00:00","2025-10-07","717608","Tobacco","2026-08-19T16:14:50.902+00:00","VIA UPS and Electronic Mail","ER2501315","2025-10-02",{"id":117,"raw":118,"subject":101,"body_html":122,"body_text":123,"firm_name":124,"letter_id":125,"created_at":18,"fei_number":19,"letter_url":126,"updated_at":127,"action_type":22,"case_status":23,"posted_date":128,"marcs_cms_no":129,"product_type":111,"closeout_date":19,"issuing_office":100,"recipient_name":19,"body_fetched_at":130,"delivery_method":113,"recipient_title":19,"reference_number":19,"action_taken_date":131,"medical_device_id":19,"response_letter_date":19},2514,[119,120,121,100,101,13,13,13],"\u003Ctime datetime=\"2022-08-16T13:20:00Z\">08\u002F16\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-08-12T04:00:00Z\">08\u002F12\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frev-products-llc-639730-08122022\">Rev Products LLC\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Rev Products LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1309 Coffeen Avenue, Suite 2579\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Sheridan\u003C\u002Fspan>, \u003Cspan>WY\u003C\u002Fspan> \u003Cspan>82801\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@revecig.com\"> info@revecig.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>August 12, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed https:\u002F\u002Frevecig.com and determined your ENDS products listed there are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and are intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see, \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14\">https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. §387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our review of the website https:\u002F\u002Frevecig.com revealed that you manufacture and offer for sale or distribution to customers in the United States ENDS products without a marketing authorization order, including: Banana Ice, Cola Ice, and Ice Grape.\u003C\u002Fp>\n\n\u003Cp>The ENDS products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&amp;C Act because a notice or other information respecting these products were not provided as required by section 905(j) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Tobacco Products Manufactured in an Unregistered Establishment Are Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our review indicates that you did not register your manufacturing establishment, located at 1309 Coffeen Avenue Suite 2579 Sheridan, WY 82801, as required by section 905(c) of the FD&amp;C Act (21 U.S.C. § 387e(c)). Specifically, section 905(c) states that “[e]very person upon first engaging in the manufacture, preparation, compounding, or processing of a tobacco product or tobacco products in any establishment owned or operated in any State by that person shall immediately register with the Secretary that person's name, place of business, and such establishment.”\u003C\u002Fp>\n\n\u003Cp>Because your establishment was not registered in accordance with section 905(c) of the FD&amp;C Act, your tobacco products that were manufactured, prepared, propagated, compounded, or processed at that establishment are misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)). The introduction or delivery for introduction into interstate commerce of any tobacco product that is adulterated or misbranded is a prohibited act under section 301(a) of the FD&amp;C Act (21 U.S.C. § 331(a)). The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&amp;C Act (21 U.S.C. § 331(k)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has not received an application from your firm requesting marketing authorization for the products listed in this Warning Letter. These products and any other new tobacco products on the market without the statutorily required premarket authorization are adulterated and misbranded and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act. It is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., and implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, RW2201806, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\u003C\u002Fp>\n\n\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact Bryan Hills at (301) 796-9367 or via email at CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nAnn Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>VIA UPS and Electronic Mail\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>cc:\u003C\u002Fp>\n\n\u003Cp>Cloud Peak Law, LLC\u003Cbr>\nAttn: Andrew Pierce\u003Cbr>\n1095 Sugar View Dr., Ste. 500\u003Cbr>\nSheridan, WY 828801\u003Cbr>\nreports@cloudpeaklaw.com\u003C\u002Fp>\n\n\u003Cp>Domains By Proxy, LLC\u003Cbr>\nabuse@domainsbyproxy.com\u003C\u002Fp>\n\n\u003Cp>GoDaddy.com, LLC\u003Cbr>\nabuse@godaddy.com\u003C\u002Fp>\n\n\u003Cp>InMotion Hosting, Inc.\u003Cbr>\nabuse@inmotionhosting.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRev Products LLC\n\n1309 Coffeen Avenue, Suite 2579\n\nSheridan, WY 82801\n\nUnited States\n\ninfo@revecig.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nAugust 12, 2022\n\nWARNING LETTER\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed https:\u002F\u002Frevecig.com and determined your ENDS products listed there are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and are intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see, https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. §387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\n\nOur review of the website https:\u002F\u002Frevecig.com revealed that you manufacture and offer for sale or distribution to customers in the United States ENDS products without a marketing authorization order, including: Banana Ice, Cola Ice, and Ice Grape.\n\nThe ENDS products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&C Act because a notice or other information respecting these products were not provided as required by section 905(j) of the FD&C Act.\n\nTobacco Products Manufactured in an Unregistered Establishment Are Misbranded\n\nOur review indicates that you did not register your manufacturing establishment, located at 1309 Coffeen Avenue Suite 2579 Sheridan, WY 82801, as required by section 905(c) of the FD&C Act (21 U.S.C. § 387e(c)). Specifically, section 905(c) states that “[e]very person upon first engaging in the manufacture, preparation, compounding, or processing of a tobacco product or tobacco products in any establishment owned or operated in any State by that person shall immediately register with the Secretary that person's name, place of business, and such establishment.”\n\nBecause your establishment was not registered in accordance with section 905(c) of the FD&C Act, your tobacco products that were manufactured, prepared, propagated, compounded, or processed at that establishment are misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)). The introduction or delivery for introduction into interstate commerce of any tobacco product that is adulterated or misbranded is a prohibited act under section 301(a) of the FD&C Act (21 U.S.C. § 331(a)). The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&C Act (21 U.S.C. § 331(k)).\n\nConclusion and Requested Actions\n\nFDA has not received an application from your firm requesting marketing authorization for the products listed in this Warning Letter. These products and any other new tobacco products on the market without the statutorily required premarket authorization are adulterated and misbranded and are subject to enforcement action at FDA’s discretion.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&C Act. It is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., and implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, RW2201806, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\n\nDPAL-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact Bryan Hills at (301) 796-9367 or via email at CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nVIA UPS and Electronic Mail\n\ncc:\n\nCloud Peak Law, LLC\n\nAttn: Andrew Pierce\n\n1095 Sugar View Dr., Ste. 500\n\nSheridan, WY 828801\n\nreports@cloudpeaklaw.com\n\nDomains By Proxy, LLC\n\nabuse@domainsbyproxy.com\n\nGoDaddy.com, LLC\n\nabuse@godaddy.com\n\nInMotion Hosting, Inc.\n\nabuse@inmotionhosting.com","Rev Products LLC","rev-products-llc-639730-08122022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frev-products-llc-639730-08122022","2026-10-26T08:09:49.092354+00:00","2022-08-16","639730","2026-08-20T01:40:04.669+00:00","2022-08-12",{"id":133,"raw":134,"subject":38,"body_html":140,"body_text":141,"firm_name":142,"letter_id":143,"created_at":18,"fei_number":19,"letter_url":144,"updated_at":145,"action_type":22,"case_status":146,"posted_date":147,"marcs_cms_no":148,"product_type":26,"closeout_date":149,"issuing_office":138,"recipient_name":150,"body_fetched_at":151,"delivery_method":152,"recipient_title":19,"reference_number":19,"action_taken_date":153,"medical_device_id":19,"response_letter_date":19},2640,[135,136,137,138,38,13,139,13],"\u003Ctime datetime=\"2022-05-31T13:20:00Z\">05\u002F31\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-03-11T05:00:00Z\">03\u002F11\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcaj-food-products-inc-624051-03112022\">CAJ Food Products Inc.\u003C\u002Fa>","Office of Human and Animal Food Operations East Division 6","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcaj-food-products-inc-624051-08042022\">\u003Ctime datetime=\"2022-08-08T04:00:00Z\">08\u002F08\u002F2022\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Matt Herzog\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>CAJ Food Products Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>11650 Olio Rd. Suite 1000\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Fishers\u003C\u002Fspan>, \u003Cspan>IN\u003C\u002Fspan> \u003Cspan>46037\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@drinkbeetjuice.com\"> info@drinkbeetjuice.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Human and Animal Food Operations East Division 6\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>\nFY22-HAFE6-05 CMS 624051\u003C\u002Fp>\n\n\u003Cp>March 11, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Herzog:\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the Food and Drug Administration (FDA) reviewed your Amazon.com storefronts at https:\u002F\u002Fwww.amazon.com\u002Fstores\u002FBiotta\u002Fpage\u002F9B960DEE-B174-4936-974D-A819B9769B6B?ref_=ast_bln and https:\u002F\u002Fwww.amazon.com\u002Fjuiceperformer?&amp;_encoding=UTF8&amp;tag=biottajuices-20&amp;linkCode=ur2&amp;linkId=d3d1183c057052af439e1da624875d15&amp;camp=1789&amp;creative=9325 in November – December 2021, and has determined that you take orders there for the products Biotta Apple Beet Ginger Juice, Biotta Beet Juice, Biotta Carrot Juice, Biotta Elderberry Juice, Biotta Golden Beet Juice Blend with Turmeric, Biotta Celery Root Juice, Biotta Breuss Vegetable Juice, Biotta Tart Cherry Juice, Juice Performer Beet Juice with Pineapple Juice, Juice Performer Beet Juice with B12, and Juice Performer Beet Juice with Passion Fruit Juice. We also reviewed your website at www.drinkbeetjuice.com, which directs consumers to your websites at www.biottajuices.com, and www.juiceperformer.com, both of which direct consumers to your Amazon.com storefronts to purchase your products. The claims on your websites establish that the products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Examples of some of website claims that provide evidence that your products are intended for use as drugs include:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Biotta product webpage claims\u003C\u002Fstrong>\u003Cbr>\n• Biotta Apple Beet Ginger Juice “Products” page (http:\u002F\u002Fwww.biottajuices.com\u002Fproducts\u002Fapple-beet-ginger-juice\u002F)\u003Cbr>\n- “Ginger: may … protect against Alzheimer’s”\u003Cbr>\n- “Helps fight cancer…Apple: reduces the risk of colon and lung cancer\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>…Beet: helps fight breast cancer, also protects from pancreatic, prostate cancers…Ginger: lowers the risk of breast, ovarian, pancreatic cancers”\u003Cbr>\n- “Apple: prevents chronic diseases … Beet: reduces blood pressure … Ginger: calms indigestion and reduces nausea”\u003C\u002Fp>\n\n\u003Cp>• Biotta Beet Juice “Products” page (http:\u002F\u002Fwww.biottajuices.com\u002Fproducts\u002Fbeet-juice\u002F)\u003Cbr>\n- “Helps reduce blood pressure … Hypertension\u002FAHA study shows 7% reduction in blood pressure … Contributes to a reduction in arterial stiffness”\u003Cbr>\n- “…may lower risk of stroke…\u003Cbr>\n- “Improved mobility for patients with COPD [chronic obstructive pulmonary disease]… Improved muscle power in patients with heart failure”\u003Cbr>\n- “May help prevent Type 2 Diabetes”\u003Cbr>\n- “Powerful … anti-inflammatory”\u003C\u002Fp>\n\n\u003Cp>• Biotta Carrot Juice “Products” page (http:\u002F\u002Fwww.biottajuices.com\u002Fproducts\u002Fcarrot-juice\u002F)\u003Cbr>\n- “Prevents … acne …”\u003Cbr>\n- “Lowers risk of cardiovascular disease”\u003Cbr>\n- “Reduces the risk of stroke”\u003Cbr>\n- “Reduces breast cancer risk…”\u003Cbr>\n- “When the liver functions well, it prevents the accumulation of fat and aids in its rapid digestion, preventing … obesity”\u003C\u002Fp>\n\n\u003Cp>• Biotta Elderberry Juice “Products” page (http:\u002F\u002Fwww.biottajuices.com\u002Fproducts\u002Felderberry-juice\u002F)\u003Cbr>\n- “[E]lderberry juice…has been effective in relieving colds and flu…”\u003Cbr>\n- “Treats respiratory illness…May help reduce swelling in mucous membranes…antiviral properties of elderberries were able to effectively inhibit the H1N1 virus, and offered similar effects to prescription medications like Tamiflu”\u003Cbr>\n- “Flavonoids in elderberries … may help prevent damage to the body’s cells … Lowers cholesterol …”\u003C\u002Fp>\n\n\u003Cp>• Biotta Golden Beet Juice Blend with Turmeric “Products” page (http:\u002F\u002Fwww.biottajuices.com\u002Fproducts\u002Fgolden-beet-juice-blend-turmeric\u002F)\u003Cbr>\n- “Improves heart health…Reduces blood pressure…Stabilizes blood sugar…Assists in fighting against heart disease”\u003Cbr>\n- “Provides powerful anti-inflammatory effects … May be effective in lowering bad cholesterol”\u003C\u002Fp>\n\n\u003Cp>• Biotta Celery Root Juice “Products” page (http:\u002F\u002Fwww.biottajuices.com\u002Fproducts\u002Fcelery-juice\u002F)\u003Cbr>\n- “Acts as a diuretic, helping neutralize pH balance and stimulating kidney function, ridding the body of toxins and allowing the body to resist disease … Reduces formation of kidney stones”\u003Cbr>\n- “Acts as an anti-inflammatory … Used to reduce effects of asthma”\u003C\u002Fp>\n\n\u003Cp>• Biotta Breuss Vegetable Juice “Products” page (http:\u002F\u002Fwww.biottajuices.com\u002Fproducts\u002Fbreuss-vegetable-juice\u002F)\u003Cbr>\n- “Ideal for Breuss cancer treatment…”\u003Cbr>\n- “Featured in Dr. Breuss’ book – The Breuss Cancer Cure: Advice for the Prevention and Natural Treatment of Cancer, Leukemia, and Other Seemingly Incurable Diseases”\u003C\u002Fp>\n\n\u003Cp>• Biotta Tart Cherry Juice “Products” page (http:\u002F\u002Fwww.biottajuices.com\u002Fproducts\u002Ftart-cherry-juice\u002F)\u003Cbr>\n- “Ideal for reducing inflammation …”\u003Cbr>\n- “Prevents gout…Tart cherry juice can combat gout, a type of arthritis that causes repeated attacks of intense pain and swelling”\u003Cbr>\n- “Good source of Potassium … Consuming foods rich in potassium may help lower blood pressure and decrease the risk of kidney stones”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Juice Performer webpage claims\u003C\u002Fstrong>\u003Cbr>\nOn a page titled “Science” in the “Beet” section of the Juice Performer website (http:\u002F\u002Fwww.juiceperformer.com\u002Fbeet-performer\u002Fscience\u002F):\u003C\u002Fp>\n\n\u003Cp>Juice Performer Beet Juice with Pineapple Juice, Juice Performer Beet Juice with B12, and Juice Performer Beet Juice with Passion Fruit Juice\u003Cbr>\n- “Beet juice also lowers blood pressure…and reduces inflammation in the body”\u003Cbr>\n- “Research has shown that a daily inorganic nitrate dose (like from Beet juice) can be as effective as medical intervention in reducing blood pressure… Some of the findings include:\u003Cbr>\n&nbsp; &nbsp;  Drinking 8 oz of Beet juice lowered systolic blood pressure by an average of 4-5 points\u003Cbr>\n&nbsp; &nbsp;  Beet juice contributed to a reduction in arterial stiffness as well as a sustained reduction in blood pressure. This was found to be as effective as prescription medication.\u003Cbr>\n&nbsp; &nbsp;  Seniors With Heart Failure Benefit From Beetroot Juice”\u003Cbr>\n- “Patients with COPD were able to improve their exercise function after drinking Beet juice.”\u003C\u002Fp>\n\n\u003Cp>Your Biotta Apple Beet Ginger Juice, Biotta Beet Juice, Biotta Carrot Juice, Biotta Elderberry Juice, Biotta Golden Beet Juice Blend with Turmeric, Biotta Celery Root Juice, Biotta Breuss Vegetable Juice, Biotta Tart Cherry Juice, Juice Performer Beet Juice with Pineapple Juice, Juice Performer Beet Juice with B12, and Juice Performer Beet Juice with Passion Fruit Juice products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your products Biotta Apple Beet Ginger Juice, Biotta Beet Juice, Biotta Carrot Juice, Biotta Elderberry Juice, Biotta Golden Beet Juice Blend with Turmeric, Biotta Celery Root Juice, Biotta Breuss Vegetable Juice, Biotta Tart Cherry Juice, Juice Performer Beet Juice with Pineapple Juice, Juice Performer Beet Juice with B12, and Juice Performer Beet Juice with Passion Fruit Juice are intended for prevention or treatment of one or more diseases that are not amenable to self-diagnosis, prevention, or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, your Biotta Apple Beet Ginger Juice, Biotta Beet Juice, Biotta Carrot Juice, Biotta Elderberry Juice, Biotta Golden Beet Juice Blend with Turmeric, Biotta Celery Root Juice, Biotta Breuss Vegetable Juice, Biotta Tart Cherry Juice, Juice Performer Beet Juice with Pineapple Juice, Juice Performer Beet Juice with B12, and Juice Performer Beet Juice with Passion Fruit Juice products fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. 331(a)].\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to the following address: U.S. Food and Drug Administration, Alecia Marson-Acting Compliance Officer, 550 W. Jackson Blvd., Suite 1500 Chicago, IL 60661. If you should have any questions regarding any issue in this letter, please contact Alecia Marson, Acting Compliance Officer, at (414) 326-3973 or email Alecia.Marson@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>William R. Weissinger, MS\u003Cbr>\nDistrict Director | FDA Chicago District\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Human and Animal Food Operations East Division 6\u003C\u002Fp>\n\n\u003Cp>____________________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Here and throughout the remainder of the letter, citations have been removed where they appear on your website.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMatt Herzog\n\nRecipient Title\n\nPresident\n\nCAJ Food Products Inc.\n\n11650 Olio Rd. Suite 1000\n\nFishers, IN 46037\n\nUnited States\n\ninfo@drinkbeetjuice.com\n\nIssuing Office:\n\nOffice of Human and Animal Food Operations East Division 6\n\nUnited States\n\nWARNING LETTER\n\nFY22-HAFE6-05 CMS 624051\n\nMarch 11, 2022\n\nDear Mr. Herzog:\n\nThis is to advise you that the Food and Drug Administration (FDA) reviewed your Amazon.com storefronts at https:\u002F\u002Fwww.amazon.com\u002Fstores\u002FBiotta\u002Fpage\u002F9B960DEE-B174-4936-974D-A819B9769B6B?ref_=ast_bln and https:\u002F\u002Fwww.amazon.com\u002Fjuiceperformer?&_encoding=UTF8&tag=biottajuices-20&linkCode=ur2&linkId=d3d1183c057052af439e1da624875d15&camp=1789&creative=9325 in November – December 2021, and has determined that you take orders there for the products Biotta Apple Beet Ginger Juice, Biotta Beet Juice, Biotta Carrot Juice, Biotta Elderberry Juice, Biotta Golden Beet Juice Blend with Turmeric, Biotta Celery Root Juice, Biotta Breuss Vegetable Juice, Biotta Tart Cherry Juice, Juice Performer Beet Juice with Pineapple Juice, Juice Performer Beet Juice with B12, and Juice Performer Beet Juice with Passion Fruit Juice. We also reviewed your website at www.drinkbeetjuice.com, which directs consumers to your websites at www.biottajuices.com, and www.juiceperformer.com, both of which direct consumers to your Amazon.com storefronts to purchase your products. The claims on your websites establish that the products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nExamples of some of website claims that provide evidence that your products are intended for use as drugs include:\n\nBiotta product webpage claims\n\n• Biotta Apple Beet Ginger Juice “Products” page (http:\u002F\u002Fwww.biottajuices.com\u002Fproducts\u002Fapple-beet-ginger-juice\u002F)\n\n- “Ginger: may … protect against Alzheimer’s”\n\n- “Helps fight cancer…Apple: reduces the risk of colon and lung cancer1…Beet: helps fight breast cancer, also protects from pancreatic, prostate cancers…Ginger: lowers the risk of breast, ovarian, pancreatic cancers”\n\n- “Apple: prevents chronic diseases … Beet: reduces blood pressure … Ginger: calms indigestion and reduces nausea”\n\n• Biotta Beet Juice “Products” page (http:\u002F\u002Fwww.biottajuices.com\u002Fproducts\u002Fbeet-juice\u002F)\n\n- “Helps reduce blood pressure … Hypertension\u002FAHA study shows 7% reduction in blood pressure … Contributes to a reduction in arterial stiffness”\n\n- “…may lower risk of stroke…\n\n- “Improved mobility for patients with COPD [chronic obstructive pulmonary disease]… Improved muscle power in patients with heart failure”\n\n- “May help prevent Type 2 Diabetes”\n\n- “Powerful … anti-inflammatory”\n\n• Biotta Carrot Juice “Products” page (http:\u002F\u002Fwww.biottajuices.com\u002Fproducts\u002Fcarrot-juice\u002F)\n\n- “Prevents … acne …”\n\n- “Lowers risk of cardiovascular disease”\n\n- “Reduces the risk of stroke”\n\n- “Reduces breast cancer risk…”\n\n- “When the liver functions well, it prevents the accumulation of fat and aids in its rapid digestion, preventing … obesity”\n\n• Biotta Elderberry Juice “Products” page (http:\u002F\u002Fwww.biottajuices.com\u002Fproducts\u002Felderberry-juice\u002F)\n\n- “[E]lderberry juice…has been effective in relieving colds and flu…”\n\n- “Treats respiratory illness…May help reduce swelling in mucous membranes…antiviral properties of elderberries were able to effectively inhibit the H1N1 virus, and offered similar effects to prescription medications like Tamiflu”\n\n- “Flavonoids in elderberries … may help prevent damage to the body’s cells … Lowers cholesterol …”\n\n• Biotta Golden Beet Juice Blend with Turmeric “Products” page (http:\u002F\u002Fwww.biottajuices.com\u002Fproducts\u002Fgolden-beet-juice-blend-turmeric\u002F)\n\n- “Improves heart health…Reduces blood pressure…Stabilizes blood sugar…Assists in fighting against heart disease”\n\n- “Provides powerful anti-inflammatory effects … May be effective in lowering bad cholesterol”\n\n• Biotta Celery Root Juice “Products” page (http:\u002F\u002Fwww.biottajuices.com\u002Fproducts\u002Fcelery-juice\u002F)\n\n- “Acts as a diuretic, helping neutralize pH balance and stimulating kidney function, ridding the body of toxins and allowing the body to resist disease … Reduces formation of kidney stones”\n\n- “Acts as an anti-inflammatory … Used to reduce effects of asthma”\n\n• Biotta Breuss Vegetable Juice “Products” page (http:\u002F\u002Fwww.biottajuices.com\u002Fproducts\u002Fbreuss-vegetable-juice\u002F)\n\n- “Ideal for Breuss cancer treatment…”\n\n- “Featured in Dr. Breuss’ book – The Breuss Cancer Cure: Advice for the Prevention and Natural Treatment of Cancer, Leukemia, and Other Seemingly Incurable Diseases”\n\n• Biotta Tart Cherry Juice “Products” page (http:\u002F\u002Fwww.biottajuices.com\u002Fproducts\u002Ftart-cherry-juice\u002F)\n\n- “Ideal for reducing inflammation …”\n\n- “Prevents gout…Tart cherry juice can combat gout, a type of arthritis that causes repeated attacks of intense pain and swelling”\n\n- “Good source of Potassium … Consuming foods rich in potassium may help lower blood pressure and decrease the risk of kidney stones”\n\nJuice Performer webpage claims\n\nOn a page titled “Science” in the “Beet” section of the Juice Performer website (http:\u002F\u002Fwww.juiceperformer.com\u002Fbeet-performer\u002Fscience\u002F):\n\nJuice Performer Beet Juice with Pineapple Juice, Juice Performer Beet Juice with B12, and Juice Performer Beet Juice with Passion Fruit Juice\n\n- “Beet juice also lowers blood pressure…and reduces inflammation in the body”\n\n- “Research has shown that a daily inorganic nitrate dose (like from Beet juice) can be as effective as medical intervention in reducing blood pressure… Some of the findings include:\n\n Drinking 8 oz of Beet juice lowered systolic blood pressure by an average of 4-5 points\n\n Beet juice contributed to a reduction in arterial stiffness as well as a sustained reduction in blood pressure. This was found to be as effective as prescription medication.\n\n Seniors With Heart Failure Benefit From Beetroot Juice”\n\n- “Patients with COPD were able to improve their exercise function after drinking Beet juice.”\n\nYour Biotta Apple Beet Ginger Juice, Biotta Beet Juice, Biotta Carrot Juice, Biotta Elderberry Juice, Biotta Golden Beet Juice Blend with Turmeric, Biotta Celery Root Juice, Biotta Breuss Vegetable Juice, Biotta Tart Cherry Juice, Juice Performer Beet Juice with Pineapple Juice, Juice Performer Beet Juice with B12, and Juice Performer Beet Juice with Passion Fruit Juice products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour products Biotta Apple Beet Ginger Juice, Biotta Beet Juice, Biotta Carrot Juice, Biotta Elderberry Juice, Biotta Golden Beet Juice Blend with Turmeric, Biotta Celery Root Juice, Biotta Breuss Vegetable Juice, Biotta Tart Cherry Juice, Juice Performer Beet Juice with Pineapple Juice, Juice Performer Beet Juice with B12, and Juice Performer Beet Juice with Passion Fruit Juice are intended for prevention or treatment of one or more diseases that are not amenable to self-diagnosis, prevention, or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, your Biotta Apple Beet Ginger Juice, Biotta Beet Juice, Biotta Carrot Juice, Biotta Elderberry Juice, Biotta Golden Beet Juice Blend with Turmeric, Biotta Celery Root Juice, Biotta Breuss Vegetable Juice, Biotta Tart Cherry Juice, Juice Performer Beet Juice with Pineapple Juice, Juice Performer Beet Juice with B12, and Juice Performer Beet Juice with Passion Fruit Juice products fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. 331(a)].\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action, including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour response should be sent to the following address: U.S. Food and Drug Administration, Alecia Marson-Acting Compliance Officer, 550 W. Jackson Blvd., Suite 1500 Chicago, IL 60661. If you should have any questions regarding any issue in this letter, please contact Alecia Marson, Acting Compliance Officer, at (414) 326-3973 or email Alecia.Marson@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nWilliam R. Weissinger, MS\n\nDistrict Director | FDA Chicago District\n\nProgram Division Director\n\nOffice of Human and Animal Food Operations East Division 6\n\n____________________________________\n\n1 Here and throughout the remainder of the letter, citations have been removed where they appear on your website.","CAJ Food Products Inc.","caj-food-products-inc-624051-03112022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcaj-food-products-inc-624051-03112022","2026-10-26T08:08:10.075522+00:00","Closed Out","2022-05-31","624051","2022-08-08","Matt Herzog","2026-08-20T01:51:26.479+00:00","Via Email","2022-03-11",{"id":155,"raw":156,"subject":161,"body_html":162,"body_text":163,"firm_name":164,"letter_id":165,"created_at":18,"fei_number":19,"letter_url":166,"updated_at":167,"action_type":22,"case_status":23,"posted_date":168,"marcs_cms_no":169,"product_type":26,"closeout_date":19,"issuing_office":160,"recipient_name":170,"body_fetched_at":171,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":172,"medical_device_id":19,"response_letter_date":19},2794,[157,158,159,160,161,13,13,13],"\u003Ctime datetime=\"2022-03-28T14:00:00Z\">03\u002F28\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-03-25T04:00:00Z\">03\u002F25\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fiodine-products-inc-628296-03252022\">Iodine Products Inc\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Gene Rosov\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Iodine Products Inc\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>8025 SW 63rd Place\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>So. Miami\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33143\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:erosov@iodineproducts.com\"> erosov@iodineproducts.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>RE: CMS# 628296\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Date: March 25, 2022\u003C\u002Fp>\n\n\u003Cp>RE: Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the United States Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) reviewed your website at the Internet address https:\u002F\u002Fwww.iodineproducts.com on March 2, 2022, and March 23, 2022, respectively. We also reviewed your social media websites at https:\u002F\u002Fwww.youtube.com\u002Fc\u002FIodineProducts\u002Fvideos, https:\u002F\u002Fwww.facebook.com\u002FIodineProducts, and https:\u002F\u002Fwww.instagram.com\u002Fiodineproducts\u002F?hl=en, where you direct consumers to your website, http:\u002F\u002Fwww.iodineproducts.com\u002F, to purchase your products. The FDA has observed that your website offers Liquid Mask Spray Anti-Viral and The COVID-Killer for sale in the United States and that these products are intended to mitigate, prevent, treat, diagnose, or cure COVID-19\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> in people. Based on our review, these products are unapproved new drugs sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. § 355(a). Furthermore, these products are misbranded drugs under section 502 of the FD&amp;C Act, 21 U.S.C. § 352. The introduction or delivery for introduction of these products into interstate commerce is prohibited under sections 301(a) and (d) of the FD&amp;C Act, 21 U.S.C. § 331(a) and (d).\u003C\u002Fp>\n\n\u003Cp>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell products that are intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fp>\n\n\u003Cp>Some examples of the claims on your website that establish the intended use of your products and misleadingly represent them as safe and\u002For effective for the treatment or prevention of COVID-19 include:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Our new Anti-Viral Liquid Mask is a COVID KILLER. Once you use it, you’re protected. Doctors use it to prevent the transmission of COVID-19 between doctors, staff and patients worldwide. It works! . . . In your mouth. Spray 2-3 times in your mouth. Breathe inwards to pull the iodine aerosol into your throat . . . In your nose . . . make sure to get 1-2 sprays directly into your nose. Sniff to pull it upward.” [from your webpage https:\u002F\u002Fwww.iodineproducts.com\u002Fproduct\u002Fliquid-mask-sprayanti-viral-large\u002F]\u003C\u002Fli>\n\t\u003Cli>“Lab and clinical studies show it kills ALL viruses, including the COVID-19 coronavirus, on contact in 15-30 seconds . . . A recent clinical study proves that the active ingredients in our 10 ml Liquid Mask CURE COVID-19 patients and simultaneously PREVENT transmission as they kill COVID-19 virus particles . . . Tags: anti-viral, COVID, COVID-19, Cure” [from your webpage https:\u002F\u002Fwww.iodineproducts.com\u002Fproduct\u002Fliquid-mask-spray-anti-viral-large\u002F]\u003C\u002Fli>\n\t\u003Cli>“The COVID-Killer 10 Ml Liquid Mask Anti-Viral Spray . . . Our 10-day 10 ml Liquid Mask is a COVID-19 virus killer. It sprays easily into nose and throat where it forms a protective coating that will last. Moreover, if you do come in to contact with a virus, such as . . . COVID . . . the iodine in the mask spray will kill is [sic] on contact within seconds . . . There are more studies that show that iodine kills COVID-19.” [from your webpage https:\u002F\u002Fwww.iodineproducts.com\u002Fproduct\u002F10-ml-liquidmask-anti-viral-nose-throat-spray-small\u002F]\u003C\u002Fli>\n\t\u003Cli>“Liquid Mask – only at iodineproducts.com – to Prevent COVID transmission . . . To truly prevent the transmission of this disease organism (the SARS-CoV-2 virus), you need Liquid Mask.” [from a January 8, 2021 post on your YouTube webpage https:\u002F\u002Fwww.youtube.com\u002Fc\u002FIodineProducts\u002Fvideos]\u003C\u002Fli>\n\t\u003Cli>“Our new free LIQUID MASK is a viral killer . . . This product in various forms is being used . . . to prevent the transmission of COVID-19 . . . PREVENT COVID! . . . Use our FREE Covid Killing Liquid Mask . . .” [from a January 11, 2021 post on your Facebook webpage https:\u002F\u002Fwww.facebook.com\u002FIodineProducts]\u003C\u002Fli>\n\t\u003Cli>“#11 of 19 Ways to Avoid Covid-19 . . . Tip #11 Get Liquid Mask . . . Liquid Mask kills the virus . . . #covid #covid_19 . . . #tipsforcovid19 #Covidtips #Covidfree . . . #covidrelief #covidliquidmasks” [from a February 28, 2021 post on your Instagram webpage https:\u002F\u002Fwww.instagram.com\u002Fp\u002FCL1eUlCHIeM\u002F]\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>You should take immediate action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the FD&amp;C Act and FDA's implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a COVID-19-related use for which they have not been approved by FDA and that you do not make claims that misbrand the products in violation of the FD&amp;C Act. \u003Cstrong>Within 48 hours, please send an email to COVID-19-Task-Force-CDER@fda.hhs.gov\u003C\u002Fstrong> describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>FDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and\u002For effective for the treatment or prevention of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the FD&amp;C Act. This list can be found at&nbsp;\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products\">http:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products\u003C\u002Fa>. Once you have taken actions to address the sale of your unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>If you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your product(s) referenced above to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.\u003C\u002Fp>\n\n\u003Cp>Please direct any inquiries to FDA at \u003Cstrong>COVID-19-Task-Force-CDER@fda.hhs.gov\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>FTC Cease and Desist Demand:\u003C\u002Fstrong> In addition, it is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made. For COVID-19, no such study is currently known to exist for the products identified above. Thus, any coronavirus-related prevention or treatment claims regarding such products are not supported by competent and reliable scientific evidence. You must immediately cease making all such claims. Violations of the FTC Act may result in legal action seeking a Federal District Court injunction and an order may require that you pay back money to consumers. In addition, pursuant to the COVID-19 Consumer Protection Act, Section 1401, Division FF, of the Consolidated Appropriations Act, 2021, P.L. 116-260, marketers who make deceptive claims about the treatment, cure, prevention, or mitigation of COVID-19 are subject to a civil penalty of up to $46,517 per violation and may be required to pay refunds to consumers or provide other relief pursuant to Section 19(b) of the FTC Act, 15 U.S.C. § 57b(b). Within 48 hours, please send an email to Richard Cleland, Assistant Director of the FTC’s Division of Advertising Practices, via electronic mail at rcleland@ftc.gov certifying that you have ceased making unsubstantiated claims for the products identified above. If you have any questions regarding compliance with the FTC Act, please contact Mr. Cleland at 202-326-3088.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Donald D. Ashley&nbsp;\u003Cbr>\nDirector&nbsp;\u003Cbr>\nOffice of Compliance&nbsp;\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Serena Viswanathan\u003Cbr>\nAssociate Director\u003Cbr>\nDivision of Advertising Practices\u003Cbr>\nFederal Trade Commission\u003C\u002Fp>\n\n\u003Cp>_____________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> As explained in the next paragraph, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at \u003Ca href=\"https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\">https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at \u003Ca href=\"https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamationdeclaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\">https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamationdeclaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\u003C\u002Fa>.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nGene Rosov\n\nIodine Products Inc\n\n8025 SW 63rd Place\n\nSo. Miami, FL 33143\n\nUnited States\n\nerosov@iodineproducts.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWARNING LETTER\n\nRE: CMS# 628296\n\nDate: March 25, 2022\n\nRE: Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\n\nThis is to advise you that the United States Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) reviewed your website at the Internet address https:\u002F\u002Fwww.iodineproducts.com on March 2, 2022, and March 23, 2022, respectively. We also reviewed your social media websites at https:\u002F\u002Fwww.youtube.com\u002Fc\u002FIodineProducts\u002Fvideos, https:\u002F\u002Fwww.facebook.com\u002FIodineProducts, and https:\u002F\u002Fwww.instagram.com\u002Fiodineproducts\u002F?hl=en, where you direct consumers to your website, http:\u002F\u002Fwww.iodineproducts.com\u002F, to purchase your products. The FDA has observed that your website offers Liquid Mask Spray Anti-Viral and The COVID-Killer for sale in the United States and that these products are intended to mitigate, prevent, treat, diagnose, or cure COVID-191 in people. Based on our review, these products are unapproved new drugs sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355(a). Furthermore, these products are misbranded drugs under section 502 of the FD&C Act, 21 U.S.C. § 352. The introduction or delivery for introduction of these products into interstate commerce is prohibited under sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d).\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.2 In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.3 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell products that are intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nSome examples of the claims on your website that establish the intended use of your products and misleadingly represent them as safe and\u002For effective for the treatment or prevention of COVID-19 include:\n\n“Our new Anti-Viral Liquid Mask is a COVID KILLER. Once you use it, you’re protected. Doctors use it to prevent the transmission of COVID-19 between doctors, staff and patients worldwide. It works! . . . In your mouth. Spray 2-3 times in your mouth. Breathe inwards to pull the iodine aerosol into your throat . . . In your nose . . . make sure to get 1-2 sprays directly into your nose. Sniff to pull it upward.” [from your webpage https:\u002F\u002Fwww.iodineproducts.com\u002Fproduct\u002Fliquid-mask-sprayanti-viral-large\u002F]\n\n“Lab and clinical studies show it kills ALL viruses, including the COVID-19 coronavirus, on contact in 15-30 seconds . . . A recent clinical study proves that the active ingredients in our 10 ml Liquid Mask CURE COVID-19 patients and simultaneously PREVENT transmission as they kill COVID-19 virus particles . . . Tags: anti-viral, COVID, COVID-19, Cure” [from your webpage https:\u002F\u002Fwww.iodineproducts.com\u002Fproduct\u002Fliquid-mask-spray-anti-viral-large\u002F]\n\n“The COVID-Killer 10 Ml Liquid Mask Anti-Viral Spray . . . Our 10-day 10 ml Liquid Mask is a COVID-19 virus killer. It sprays easily into nose and throat where it forms a protective coating that will last. Moreover, if you do come in to contact with a virus, such as . . . COVID . . . the iodine in the mask spray will kill is [sic] on contact within seconds . . . There are more studies that show that iodine kills COVID-19.” [from your webpage https:\u002F\u002Fwww.iodineproducts.com\u002Fproduct\u002F10-ml-liquidmask-anti-viral-nose-throat-spray-small\u002F]\n\n“Liquid Mask – only at iodineproducts.com – to Prevent COVID transmission . . . To truly prevent the transmission of this disease organism (the SARS-CoV-2 virus), you need Liquid Mask.” [from a January 8, 2021 post on your YouTube webpage https:\u002F\u002Fwww.youtube.com\u002Fc\u002FIodineProducts\u002Fvideos]\n\n“Our new free LIQUID MASK is a viral killer . . . This product in various forms is being used . . . to prevent the transmission of COVID-19 . . . PREVENT COVID! . . . Use our FREE Covid Killing Liquid Mask . . .” [from a January 11, 2021 post on your Facebook webpage https:\u002F\u002Fwww.facebook.com\u002FIodineProducts]\n\n“#11 of 19 Ways to Avoid Covid-19 . . . Tip #11 Get Liquid Mask . . . Liquid Mask kills the virus . . . #covid #covid_19 . . . #tipsforcovid19 #Covidtips #Covidfree . . . #covidrelief #covidliquidmasks” [from a February 28, 2021 post on your Instagram webpage https:\u002F\u002Fwww.instagram.com\u002Fp\u002FCL1eUlCHIeM\u002F]\n\nYou should take immediate action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the FD&C Act and FDA's implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a COVID-19-related use for which they have not been approved by FDA and that you do not make claims that misbrand the products in violation of the FD&C Act. Within 48 hours, please send an email to COVID-19-Task-Force-CDER@fda.hhs.gov describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure and injunction.\n\nFDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and\u002For effective for the treatment or prevention of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the FD&C Act. This list can be found at http:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products. Once you have taken actions to address the sale of your unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nIf you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your product(s) referenced above to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.\n\nPlease direct any inquiries to FDA at COVID-19-Task-Force-CDER@fda.hhs.gov\n\nFTC Cease and Desist Demand: In addition, it is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made. For COVID-19, no such study is currently known to exist for the products identified above. Thus, any coronavirus-related prevention or treatment claims regarding such products are not supported by competent and reliable scientific evidence. You must immediately cease making all such claims. Violations of the FTC Act may result in legal action seeking a Federal District Court injunction and an order may require that you pay back money to consumers. In addition, pursuant to the COVID-19 Consumer Protection Act, Section 1401, Division FF, of the Consolidated Appropriations Act, 2021, P.L. 116-260, marketers who make deceptive claims about the treatment, cure, prevention, or mitigation of COVID-19 are subject to a civil penalty of up to $46,517 per violation and may be required to pay refunds to consumers or provide other relief pursuant to Section 19(b) of the FTC Act, 15 U.S.C. § 57b(b). Within 48 hours, please send an email to Richard Cleland, Assistant Director of the FTC’s Division of Advertising Practices, via electronic mail at rcleland@ftc.gov certifying that you have ceased making unsubstantiated claims for the products identified above. If you have any questions regarding compliance with the FTC Act, please contact Mr. Cleland at 202-326-3088.\n\nSincerely,\n\n\u002FS\u002F\n\nDonald D. Ashley\n\nDirector\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration\n\nSincerely,\n\n\u002FS\u002F\n\nSerena Viswanathan\n\nAssociate Director\n\nDivision of Advertising Practices\n\nFederal Trade Commission\n\n_____________________________\n\n1 As explained in the next paragraph, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\n\n2 Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\n\n3 Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamationdeclaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.","Iodine Products Inc","iodine-products-inc-628296-03252022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fiodine-products-inc-628296-03252022","2026-10-26T08:09:00.755596+00:00","2022-03-28","628296","Gene Rosov","2026-08-20T02:04:46.116+00:00","2022-03-25",{"510k":174,"classification":175,"enforcement":176,"event":177,"event_backfill":178,"pma":179,"warning_letter":180},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-18T04:00:44.748+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]